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PBPK modelingAlthough oral drug delivery is the preferred administration route and has been used for centuries, modern drug
discovery and development pipelines challenge conventional formulation approaches and highlight the insuffi-
cient mechanistic understanding of processes critical to oral drug absorption. This review presents the opinion
of UNGAP scientists on four key themes across the oral absorption landscape: (1) specific patient populations,
(2) regional differences in the gastrointestinal tract, (3) advanced formulations and (4) food-drug interactions.
The differences of oral absorption in pediatric and geriatric populations, the specific issues in colonic absorption,
the formulation approaches for poorly water-soluble (small molecules) and poorly permeable (peptides, RNA
etc.) drugs, as well as the vast realm of food effects, are some of the topics discussed in detail. The identified con-
troversies and gaps in the current understanding of gastrointestinal absorption-related processes are used to cre-
ate a roadmap for the future of oral drug absorption research.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://
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Oral absorption is the cornerstone of oral drug delivery, which is the
most convenient and widely used administration route. Decades of re-
search have considerably advanced understanding of the critical ana-
tomical, physiological, and drug formulation factors that control oral
bioavailability, as recently reviewed [1–5]. This better understanding
of physiological function and formulation functionality has been used
in the design of better oral medicines: improved controlled-release
drug delivery vehicles, enabling technologies for drugs with poor bio-
pharmaceutical properties and tailored approaches for special popula-
tions have been developed.
However, the simultaneous impact of several drivers has changed
the oral absorption landscape considerably in the last years. The realiza-
tion that peptides, proteins and nucleic acids can be potent medicinal
agents has now split modern drug discovery pipelines in two separate
streams: classical, small-molecule therapeutics [5] and high molecular
weight biologicals [4,6,7]. These two directions in the development of
therapeutic entities have strikingly different (even completely oppo-
site) physicochemical and biopharmaceutical properties, which pose
specific challenges to their oral delivery.
The selection of highly potent smallmolecules duringdrugdiscovery
has been seen as a cause of the extremely poor solubility of many new
drug candidates that emerge frommodern drug development pipelines
[8–10]. As a result, the oral absorption of such compounds is frequently
solubility or dissolution rate-limited.
In contrast, biologicals are usually characterized by sufficient solubil-
ity, but very poor intestinal permeability [4,6,7]. In addition, they face
considerable stability challenges in the enzyme-rich intestinal environ-
ment. This paradigm shift in drug development has created a strong
driving force for the development of biopredictive in silico and in vitro
tools to support both academia and the pharmaceutical industry, as
well as aid regulatory decisions [11–17]. At the same time, new discov-
eries in human physiology (e.g. intestinal fluid pockets, extent of vari-
ability) illustrate the possible complexities of oral absorption, and
raise questions about the validity of the in vitro methods currently
used in the pharmaceutical community [18–22].
The outlined challenges in oral drug delivery inspired the creation of
the European Network on Understanding Gastrointestinal Absorption-
related Processes (UNGAP, www.ungap.eu), which aims to improve
the understanding of intestinal drug absorption by creating a multidis-
ciplinary network of researchers from academia and industry. The net-
work consists of 500+ members from 32 countries and four working
groups (WGs) across key themes of oral drug absorption: special popu-
lations (WG1), regional differences (WG2), advanced formulations
(WG3) and food-drug interactions (WG4).291Therefore, the aim of this paper is not to provide a comprehensive
review of the state-of-the-art, but instead to present the opinion of
UNGAP scientists on specific controversial topics, identify critical
knowledge gaps and provide an outlook on future research activities.
The paper is largely structured according to the four main WGs in
UNGAP, with the addition of a special methodology section focused on
in vitro and in silico tools.2. Specific patient populations
2.1. Introduction and scope
The rate and extent of intestinal absorption are key properties to de-
termine the bioavailability of orally dosed drugs. In pharmaceutical de-
velopment, the prediction of these properties plays an important role in
the design and testing of new drugs and a combination of in vitro and in
silico tools is typically used for this purpose. Biorelevant tools, including
artificial gastrointestinal tract (GIT) fluids [23–27] and physiologically-
based biopharmaceutical models [17,28], have been developed and val-
idated based on the extensively characterized GIT physiology in healthy
adults. First-in-human trials are also usually conducted in healthy adult
volunteers to provide information about the pharmacokinetic (PK)
properties of a compound. However, these conditions are often not rep-
resentative for the GIT in a specific patient population, in which oral
drug absorption (in addition to other PK properties) is often signifi-
cantly different to the “average” patient [1,29–31].
Changes in GIT physiology and oral drug absorption can be triggered
by local diseases in the GIT (e.g., inflammatory bowel disease (IBD), in-
fectious diseases, celiac disease, cancer) [1,29,32–34] or systemic dis-
eases (e.g., Parkinson's disease, diabetes, HIV, critical illness)
[1,31,35–37]. In addition to the disease-dependent factors, differences
in GIT physiology have been described for non-disease dependent con-
ditions such as age, ethnicity, sex, or diet [1,38–41]. These population-
specific GIT conditions and their impact on absorption are still poorly
characterized [1]. Amongst the main reasons are the ethical constraints
associated with the conduct of research in populations including chil-
dren or critically-ill patients. Secondly, specific patient populations are
often very heterogeneous in terms of severity of the disease, co-
medications, co-morbidities, or ontogeny. The characterization of a
“standard patient population” for specific diseases thus becomes very
challenging. Finally, there is poor availability of GIT physiology and clin-
ical PK data for specific patient populations. These knowledge gaps re-
sult in substantial limitations in the development and validation of
in vitro and in silico tools representative of special populations, which
is a critical gap in the development of new medicines [42,43]. It may
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tients resulting in potential safety and/or efficacy issues for a given drug.
The generation and availability of physiology reference data will un-
derpin the development of advanced tools representative of specific
populations. Such innovative tools will require extensive validation to
build confidence in their predictive power and, for this purpose, the
availability of clinical PK data in healthy vs. diseased patients is critical.
Such research at the interface between (bio-)pharmaceutics and clinical
practice requires close cross-functional collaboration between pharma-
ceutical scientists, clinical pharmacologists, and medical practitioners
from academia, hospitals and the pharmaceutical industry to leverage
the potential of diagnostic or medical procedures (e.g. magnetic reso-
nance imaging (MRI), surgical interventions) to gain insights into the
physiology of specific patient populationswhilstminimizing the burden
to individual patients.
The opinion of the UNGAP network about the current state, chal-
lenges and opportunities in selected hot-topics across the broad
theme of specific patient populations is presented in the following sec-
tions, starting with age-segregated populations (pediatrics and geriat-
rics) and populations suffering from specific diseases (cardiovascular,
renal and metabolism diseases; IBD and COVID19). The main gaps and
the proposed way forward in the oral absorption research for age-
segregated and disease-specific populations are summarized in Figs. 1
and 2, respectively.
2.2. Pediatrics and geriatrics
The following paragraphs will focus on specific aspects of oral ab-
sorption in pediatric populations, such as the role of GIT fluid volumes,
intestinal drug transport and metabolism, food effects, as well as the
current state of pediatric in vitro and in silico tools. At the end of the sec-
tion, the largely unexplored field of oral absorption in geriatric patients
will be introduced.
2.2.1. The role of GIT fluid volumes in pediatric populations
Disintegration and dissolution of orally administered solid dosage
forms is critical prior to absorption of a drug. The volume and localiza-
tion of fluidwithin the GITwill influence the relative rates of disintegra-
tion, dissolution and ultimately absorption. Thus knowledge of the
relevant volumes (and their distribution) in pediatric populations is
important to predict the absorption and design appropriate in vitro dis-
solution apparatus; assign age-appropriate biopharmaceutics classifica-
tion system (BCS) to drugs and to better understand some of the
variability associated with PK profiles.
A very useful, non-invasive technique to visualize and measure the
small bowel water content, which has been established in the clinicalFig. 1. Pediatrics and g
292management of enteric disorders and bowel motility, is MRI [44].
Existing MRI data suggests that gastric and small intestinal fluid vol-
umes in children are much lower than in adults [21].
The colon is another attractive site for drug delivery of both locally
acting drugs andmodified release formulations. It is widely appreciated
that fluid volumes there are low, as the function of the colon is to re-
cover water, whereby the luminal contents become progressively
drier as they move through the colon. The data on available fluid in
the colon is scarce, with only two studies having been reported for
adults [20,45] and there are no data reported on fluid within the colon
of pediatric patients. A better understanding of the colonic environ-
ment, particularly the fluid volume, location and motion, would facili-
tate the design of appropriate in vitro and in silico tests to predict the
performance and variability associated with local or modified release
formulations in pediatric populations.
Unfortunately, there aremany knowledge gaps in the area of pediat-
ric GIT volumes. Fundamentally, the very limited data currently avail-
able has come from routine clinical MRI scans and thus might not
represent the norms for a “healthy” population. The data has come
from the extremes of fasted and fluid fed children, which are not repre-
sentative of the typical patient [21] and are likely to show extensive var-
iability. The existing data on GIT fluid volumes in children is
insufficiently robust to fully represent the variability associated with
fluid volumes that contributes to the overall variability observed in PK
bioequivalence (BE) studies.
In addition, MRI methodology is limited to visualization of bulk
fluids and the resolution of images does not currently allow fluid vol-
umes at the absorptive surface to be quantified. Thus despite fluid
being evident in MRI as present in temporary pockets, there is likely
to be a continuous fluid layer at the absorptive surface and the mixing
between the bulk and this layer is unknown.
Advances inMRI including the use of dynamic and filmedmeasure-
ments will facilitate non-invasive measurement of intestinal motility,
GIT transit times, as well as volumes present within the stomach, small
intestine and colon [46]. Application of these minimally invasive tools
to a pediatric population would enable the design of predictive in vitro
and in silico tools, whilstminimizing the burden of clinical testing in pe-
diatric populations. However, due to the ethical burdens associatedwith
the conduct of clinical testing in pediatric populations, there is a need to
mine existing data sets and to use advanced in silicomodels to elucidate
the likely variability and consequences of diverse fluid volumes. If these
were judgedsufficientto justifyaclinical investigation, thentherationale
for the development of predictive pediatric absorption tools is provided,
ultimately reducing clinical testingwhilst improving therapy.
The impact of disease in the pediatric population should also be con-
sidered. A large number of children suffer at some pointwith GIT issues,eriatrics summary.
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on GIT fluid volumes and subsequent oral drug absorption is currently
unknown. A better understanding of the difference in GIT fluid present
in children with these disorders would provide understanding on the
conditions under which to administer medicine. For instance, should
there be greater emphasis on administration with water in a consti-
pated child? Furthermore, differences in malnourished compared to
healthy pediatric populations have been reviewed [47] where there
are likely to be large differences in drug absorption; thus knowledge
of fluid volumes and localization can provide insights into administra-
tion or dosing adjustments.
An ideal dataset would provide real time visualization of fluid vol-
umes paired with PK data; an example of such a dataset has only re-
cently been generated for adults [48], so it is unlikely to be available
from a pediatric population. In spite of this limitation, we should not
simply exclude children fromclinical testingdue to ethical complexities,
as it is essential that pediatric populations gain access to appropriate
medicines. Therefore, excluding them from trials is ethically
questionable.2.2.2. Ontogeny of intestinal drug transport and metabolism in pediatric
populations
A survey of knowledge on intestinal drug metabolism and transport
reveals large information gaps for children as patients compared to
adults [1]. Consequently, dose predictions of orally administered
drugs, based on system information of oral absorption processes are
metwith uncertainty. This was illustrated by a recently developed pedi-
atric absorption physiologically-based pharmacokinetic model (PBPK)
[41]. At the same time, limited data from ex vivo studies on intestinal
and hepatic CYP3A, as well as oral bioavailability PK data of midazolam
(as marker of CYP3A) suggest a different intestinal vs hepatic matura-
tion pattern than suggested by a physiology-based population PK
model [49,50].
Moreover, the newest methodology to determine protein abun-
dance, i.e. LC-MS proteomics, shows large inter-lab variability and
hence, results from pediatric proteomics studies addressing drug-
metabolizing enzymes and drug transporter ontogeny should be used
carefully, and/or validated in other cohorts and laboratories [51].
Therefore, while some ontogeny data from drug-metabolizing en-
zymes and drug transport studies is available, future studies covering
thewhole pediatric age range, elucidating protein abundance and activ-
ity, using proteomics and Ussingmethodology are highly desirable [52].
As discussed in a recent White Paper, variability in proteomics re-
sults can potentially be explained by differences in sample collection
e.g. fresh, snap-frozen or formalin-fixed tissue, postsurgical or postmor-
tem tissue [51]. Moreover, as drug-metabolizing enzymes and drug
transport expression changes along the intestinal tract and different
surgical techniques are used to collect tissue (e.g. biopsy vs. whole tis-
sue) this further contributes to variation. On a more analytical level
cell fractions used (e.g. membrane fractions vs cell lysates) and mea-
surement techniques further introduce variability (e.g. global vs.
targeted proteomics). Most of these issues are not specific for pediatrics,
but apply to proteomic studies in general [51]. However, differences in
underlying disease, medication use, access to specific intestinal areas
and sample size limitations in neonates/young infants may contribute
to variability in proteomics results between children and adults, which
reflect ‘age-related’ differences in methodology, rather than true age-
related variation in protein expression.
Despite the development of innovative techniques like proteomics,
one of the main roadblocks remains the scarcity of pediatric intestinal
tissue. Innovative methodologies should be developed to overcome
this limitation, e.g. intestinal derived organoids [53]. Amethod for grow-
ing functional intestinal organoids (enteroids) from human intestine
has recently been developed [54].293Even biopsy size tissue samples can be used to grow these enteroids,
which can not only be used over many weeks, but can also be cryopre-
served for use at a later stage. Whilst the original intestinal enteroids
grow in 3D conformation with the intestinal lumen inside, they can be
converted to 2D tissue layers, which can be used to study drug transport
and metabolism [55]. To be able to use organoids to elucidate matura-
tion of drug-metabolizing enzymes and drug transporters, it is of para-
mount importance to understand if and how these organoids mature
with increasing passages.
Finally, while the combination of ex vivo methodology with PBPK
modeling is a strong tool to predict oral drugdisposition in children, val-
idation of these models using PK or phenotyping studies is needed.
Collaborative research is required to close the information gap on
drug-metabolizing enzymes and drug transporters protein expression
and activity, potentially combining, usually limited sample sets, to
cover the neonatal (0–30 days of age) and the rest of the pediatric life
age range.When using proteomics to determine drug-metabolizing en-
zymes and drug transporters expression, the challenges associatedwith
inter-laboratory variability should be acknowledged and reporting
should reflect how challenges were addressed. The lack of pediatric tis-
sue may be overcome by the use of intestinal epitheloid organoids, pro-
vided their age-specific properties are elucidated. Validation of results
from ex vivo studies in vivo, including PBPK models based on this infor-
mation, should be performed, potentially using innovative methodol-
ogy for phenotyping such as liquid biopsies for drug-metabolizing
enzymes and drug transporter genes, as well as microdosing [56,57].
2.2.3. Oral drug absorption in infants including food effects
Oral delivery is the usual route for drug administration to infants
(1 month–2 years). Understanding drug and drug formulation perfor-
mance in relation to the prandial conditions is essential for ensuring
safety and efficacy of products to be administered to pediatric patients,
especially infants whose diet has limited variation (100% milk in in-
fants < 5 months). Whether differences in the formulation design
and/or dosing (including the co-administered food) substantially im-
pacts pediatric PK is likely drug and formulation dependent, with
some drugs/formulations being at a higher risk of significant changes
than others [58,59].
Based on a recent draft guidance issued by the U.S. Food and Drug
Administration (FDA), when the same to-be-marketed formulation
that is approved for use in adults is approved for use in a pediatric pop-
ulation, a separate food effect study is not necessary and the same may
also apply in case the pediatric formulation is very similar to the adult
formulation and has been approved based on in vitro dissolution tests
[60]. Although this may be a practical approach, based on nine datasets
from food effect studies (seven drugs) in adults vs infants and young
children reported in the literature [61,62], only one study highlighted
a similar food effect in infants and in adults [62], as highlighted by
Statelova et al. [40].
The same draft guidance suggests that when the pediatric formula-
tion is not similar to the adult formulation, food effects could be evalu-
ated in adults. This would be achieved by using foods commonly
consumed with drugs by pediatric patients (e.g. formula for infants,
apple sauce for toddlers) and extrapolating the results to the pediatric
population [60].
However, it has been shown by Statelova and colleagues that food
effects on drug absorption in infants may not be adequately evaluated
from the data collected as suggested by regulatory agencies for adult
drug products, even for drugs with non-problematic absorption, no in-
testinal permeability limitations, highly soluble in the small intestine,
no documented intraluminal interactions with food components and
administered in simple dosage forms [63]. The investigated dosing con-
ditions included administration of pediatric drug formulations under
fasted conditions, fed conditions as proposed by current regulatory
guidelines for adults (30 min after the start of the consumption of the
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drug formulationwas administered during infant formula consumption,
i.e. infant-formula fed conditions. That study revealed reduced early ex-
posure of paracetamol and ibuprofen after administration under infant
fed conditions, compared to the administration under the fasted or ref-
erence meal fed conditions in adults. In addition, using PBPK modeling,
successful predictions of observed paracetamol plasma concentration
(Cp) levels in infants were achieved when extrapolating from fasted
conditions and infant-fed conditions adult data whereas data collected
following the consumption of the FDA breakfast appeared to be less
useful [63].
Clinical studies (especially, well-controlled clinical studies) in in-
fants are limited, due to ethical concerns. Difficulties in recruitment
are reflected by the limited number of food effect studies in infants pub-
lished to date. The determination of gastric emptying rates and luminal
composition (including thepH) in infants is challenging, due to frequent
meal administration, therefore, food-related physiological responses in
infants are difficult to evaluate [40,64]. Collaboration with pediatricians
to collect more data i.e. aspirates from intubated infants in order to de-
termine key physiological characteristics of the GIT relevant to oral drug
absorption and/or plasma data collected under well-defined conditions
is of paramount importance.
Relevant advances will be useful in order to better design food effect
studies in adults for the evaluation of pediatric products and will im-
prove in vitro methodologies used to evaluate GIT transit and
intraluminal dosage form performance in infants. In addition, relevant
informationwill be useful to the development of in silicomethodologies
for evaluating the PK of oral drug products in infants [63,65].
2.2.4. Biorelevant dissolution testing and in silico modeling to predict phar-
macokinetics in neonates and pediatrics
Although significant progress has been made in recent years to un-
derstand and model how oral formulations behave in neonates and pe-
diatrics [40,58,66–71], drug absorption in these populations remains
difficult to study and poorly characterized. This limits the ability to
(1) confidently extrapolate formulation performance from adult to pe-
diatric/neonate, (2) identify whether changing how a formulation is ad-
ministered alters performance and (3) meaningfully de-risk BE studies
for pediatric formulations.
Of the various pediatric sub-groups, neonates present the biggest
challenge, as controlled in vivo studies in this age group can be espe-
cially difficult (or even impossible) to perform, and because this sub-
group is most differentiated from adults.
Attempts have been made to develop in vitro dissolution tests for
predicting pediatric formulation behavior [40,59,71], including the im-
pact of co-administered food [67,72] to predict in vivo performance,
but the tools currently available still need more development and vali-
dation. The use of compendial in vitro methods for pediatric formula-
tions has been advocated and explored, as these have the advantage of
relative simplicity, but in practice, it is difficult to build in the appropri-
ate levels of biorelevance required [1].
Flow through methods (United States Pharmacopoeia (USP) IV ap-
paratus) and scaled down versions of compendial methods have been
proposed as apparatus more suitable for examining pediatric formula-
tions [40] mainly due to the ability to use smaller volumes, but these
methods still cannot mimic other key aspects relevant to pediatric for-
mulation performance, such as gut motility, dynamic fluid movement,
the impact of co-administered food digestion, etc.
Therefore, a different approach is needed. The use of complex non-
compendial in vitro tools, capable of mimicking volumes, dynamics,
meals and their digestion, in both adults and in different aged children
under different dosing conditions could be of high value for pediatric
formulation performance prediction scenarios. This would be especially
valuable if the output of these models could be combined with PBPK
modeling tools, which can in principle take into account other pediatric
specific factors, such as relevant levels of metabolizing enzymes.294Limitedwork has been performedwith complex in vitro tools. Proto-
cols have been proposed for the TNO (gastro-)intestinal model 1 (TIM-
1) [73], but other complex in vitro tools may be equally valid for use to
simulate pediatric formulation performance [40,67,72]. Ultimately, if
proven successful, these approaches could replace some adult relative
bioavailability (RBA) formulation comparison studies used in the esti-
mation of pediatric PK. This in turn would generate predictions that
can be usedwith greater confidencewhen first administering oralmed-
icines to children, or administering a formulationmodified for palatabil-
ity. For higher risk drugs, these approaches could then be used to
supplement an adult RBA study to increase the confidence of determin-
ing appropriate doses (and appropriate modifications for dosing) for
different aged children.
Another scenario where a combination of complex in vitro tools and
modeling could ultimately be usefully applied is when a pediatric for-
mulation is changed post launch and BE studies would normally be re-
quired. BE studies for pediatric formulations in children are
challenging to perform, and routes to achieving biowaivers (desirable
given the challenges of dosing to children) are poorly defined.
2.2.5. Oral drug absorption in older people and geriatric patients
According to EMA, older people can be defined as individuals older
than 65 years of age without any diagnosed chronic disease or impair-
ment, whereas geriatric patients are older peoplewith at least one diag-
nosed chronic disease or impairment [74]. The elderly (>65 years)
represent more than 20% of the global population and this percentage
is expected to grow to 35% in 2050. Older age is accompanied by an in-
crease in the number and complexity of illnesses, including that of
chronic diseases. Although geriatric patients are the main end-users,
they are under-represented in clinical trials due to advanced age,
multi-morbidity or polypharmacy [75] and current drug formulations
are based on clinical studies of adults aged 18–55 years, meaning that
a crucial part of the population in need of medications is not considered
during key steps of drug development.
Based on the fact that the majorities of geriatric patients in primary
care lives and manage their therapy independently or with the support
of relatives or caregivers, the oral route of administration remains the
route of choice. Administration of oral drug products can be problematic
for geriatric patientswith swallowing difficulties (dysphagia). The prev-
alence of dysphagia in the general population is 16–23% increasing to
27% in people aged over 76 years [76,77]. This number escalates in peo-
ple suffering fromAlzheimer's and Parkinson's diseases, aswell as other
forms of dementia and neurological conditions [78]. In addition, ageing
alters the physiological characteristics of the GIT, thus affecting oral
drug absorption. Apart from alterations in gastric pH values compared
tohealthy adults [79], other luminal characteristics have not been inves-
tigated in older people and in geriatric populations. Data on gastric
emptying rates in adults vs. older people that have been published for
the fed state are conflicting, and/or not relevant for orally administered
drug dosage forms [80,81]. The luminal environment in the lower intes-
tine of older people has been investigated for the first time, recently,
under both fasted and fed state conditions. Median pH of contents of
proximal colon of older people (6.4 in the fasted state and 5.8 in the
fed state [82]) were lower than median pH values in young adults (7.8
in the fasted state and 6.0 in the fed state [83]), but the difference
reached significance only in the fasted state [82]. Information on age-
related differences in bacterial degradation of drugs in the lower intes-
tine is limited as well [84].
Methodologies already applied in adults can be used in order to gen-
erate information on the actual dosage from intake conditions for older
people and geriatric patients and on physiological characteristics of
their GIT lumen relevant to drug absorption. The oesophageal transit
of oral dosage forms could be investigated using established clinical
techniques such as Magnetic Resonance Imaging [85,86]. The gastric
emptying of fluids and solid foods and the transit time of solid oral for-
mulations could be investigated using the salivary tracer technique [87].
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iology of older people, but they have certain limitations. Where direct
sampling using intubation is required, multiple sampling can be prob-
lematic for older people and geriatric patients as intubation usually can-
not last for more than expected for routine medical examination due to
ethical reasons. In order to evaluate the potential of paracellular drug
absorption after oral drug administration to older people, the leakiness
of GIT epithelium of older people and its impact on oral drug absorption
can be studied using the triple sugar tests [88]. Bacterial drug degrada-
tion in the lower intestine and its clinical relevance can be further inves-
tigated using fecal material [89].
Advances in the determination of key physiological characteristics of
the GIT relevant to oral drug absorption in older people and geriatric pa-
tients will be useful for the optimization of oral dosage forms based on
real life dosing conditions. This information will enable the development
of in vitro methodologies to evaluate swallowability, GIT transit, and
intraluminal dosage form performance and in silicomodels for evaluating
the PK of oral drug products for older people and geriatric patients.2.3. Disease-specific populations
2.3.1. Cardiovascular, renal and metabolism diseases
Cardiovascular, renal andmetabolism (CVRM) diseases are one of the
major disease areas by means of prevalence and mortality, and include
diseases such as diabetes, obesity, heart failure and infarction, hyperlipid-
emia, hypertension and chronic kidney disease. Biopharmaceutics aspects
of CVRMdiseases can have different origins related to physiological influ-
ence of the disease itself, common co-morbidities, old age or effects of co-
medication. Factors potentially influencing drug absorption thatmight be
affected includeGIT transit, GITfluid volumes and composition, bile secre-
tion and intestinal permeability. A non-comprehensive list of examples is
provided for illustration in Table 1. The delay in gastric emptying in dia-
betic patients even leading to gastroparesis is well known [90]. In addi-
tion, diabetes has shown to have impact on mucosa thickness both in
the small intestine and the colon [91], which is of potential importance
for drug permeability. Furthermore, acute myocardial infarction can also
lead to gastroparesis due to the trauma and/or morphine treatment as
well influencing bile secretionwhich can have critical effects on concom-
itant oral medications [92]. Some data is available in relation to oral drug
absorption in obese patients subject to bariatric surgery including in silico
modeling [93,94]. Overall, systematic investigations are needed, in order
to generate the necessary “system characterization” followed by imple-
mentation and validation in oral biopharmaceutics tools like in vitrodisso-
lution tests and PBPK.Fig. 2. Disease-specific po
295As a first step, there is a need to assemble a literature review based
on physiological and clinical science journal papers with the primary
purpose of obtaining more comprehensive data regarding factors
influencing absorption for a defined list of major CVRM diseases. Sec-
ond, patient PK data for different relevant diseases should be gathered.
A first set of modeling work of these PK data should be performed using
existing tools such as GastroPlus© or Simcyp© based on the disease-
specific factors obtained from the first stage of the review also including
common co-morbidities. These modeling efforts will help to identify
gaps by means of understanding PK performance in these patients as
well as provide a first validation of initial computer models. In a next
stage, novel in vivo mechanistic studies in patients are needed to test
novel hypotheses and fill knowledge gaps generated through the initial
modeling work. This data set will improve the PBPK models for the dif-
ferent disease stages and a final re-validation should be performed. This
approachmay also be applied to disease areas outside CVRM, if success-
ful. Public-private partnership projects can be especially useful for real-
ization of the outlined future research work.2.3.2. Inflammatory bowel disease
Oral absorption from the GIT in patients with IBD is of particular in-
terest, as differences in the PK of orally administered drugs between
healthy subjects and patients with IBD have been observed, but rarely
assessed in clinical trials.
GIT fluids in IBD patients have been shown to be different from
healthy adults in terms of their composition (i.e. proteins, lecithin, bile
salts levels) and their physicochemical properties (i.e. osmolality, pH,
buffer capacity) [1,29]. Moreover, the IBD population includes a range
of sub-populations: the type of disease (i.e. Crohn's disease, CD and Ul-
cerative Colitis, UC) and disease states (i.e. remission and relapse)
should be considered. The current knowledge with respect to GIT phys-
iology of these populations has recently been reviewed [1,29] and it was
shown that altered drug product performance could be attributed to
pathophysiological alterations (i.e. GIT transit time, fluids composition
and permeability).
In order to obtain a better understanding of solubility and dissolu-
tion in the GIT of IBD patients, GIT fluids should be collected and charac-
terized. Characterization typically includes pH, osmolality, bile salt
composition/concentration, surface tension and buffer capacity. Avail-
able data is scarce, but it is being generated: e.g. the ascending colonic
fluids of UC patients in relapse or remission have been characterized
[95]. Such fluids can be used for the characterization of new drugs, spe-
cifically intended for IBD patients, or for the optimization of simulated
IBD GIT fluids that could be integrated in dissolution tests linked to
PBPK models.pulation's summary.
Table 1
Examples of disease related impact on oral drug absorption through biopharmaceutics mechanisms.
Disease Origin of critical effect Impact biopharmacutical factor Potential impact oral absorption Ref.
Diabetes Hyperglycemia effects affecting
hormonal control
Reduced gastric emptying rate
Thickening intestinal mucosa
Slower rate of absorption
Reduced oral bioavailability if non-linear first pass
metabolism due to slower rate
Delayed onset of action
Increased drug degradation if sensitive to acid in
stomach







Reduced gastric emptying rate
Reduced bile secretion
See above
Reduced absorption of low solubility drugs
[92]
Obesity Gastric bypass surgery Reducing the gastric volume and bypassing the
duodenum and proximal jejunum
Reduced extent of absorption for low permeability
and low solubility drugs
Increased absorption for drugs with intestinal
metabolism
[93,94]
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testine and colon of IBD patients were developed and used to assess
the risk of altered luminal drug solubility depending on the physico-
chemical properties (ionization, lipophilicity) of the drug [96,97]. Fur-
ther developing the concept, biorelevant media for CD patients have
been used for drug release studies coupled with mechanistic PBPK
modeling, resulting in a successful prediction of drug performance in
the patient population [29].
Intestinal permeability in IBD patients should also be considered.
Limited information is available on the extent of increased tight junction
permeability, or on the impact of inflammation,which decreases the ab-
sorption surface area and the permeation rate [1]. These effects are
likely to depend on the severity and type of disease. Once this data is ob-
tained, in vitro permeationmodels should be developed that better rep-
resent the conditions in IBD patients.
Another critical point when administering oral drugs to IBD patients
is the frequent use of formulations based on pH-dependent coatings
[98]. In this case, factors such as transit time and pH will impact
in vivo performance, if altered by disease.
Finally, PK data should be collected comparing the IBD patient pop-
ulations and healthy volunteers, potentially using formulations with
targeted drug release profiles. In vitro and PBPK models should be fur-
ther developed and validated, based on the obtained insights from the
clinic. These tools should include all the pathophysiological changes rel-
evant for drug absorption in patients with IBD compared to healthy
subjects.
2.3.3. COVID-19
Literature data about drug absorption in COVID-19 patients are incon-
sistent and controversial. The hypothesis that the coronavirus can infect
and replicate in the GIT was confirmed by the identification of the
SARS-CoV-2 RNA in infected patients stool, and by the high expression
of the viral receptor angiotensin converting enzyme 2 (ACE2) in absorp-
tive enterocytes [99–101]. Recent in vitro studies on ileal cells exposed
to SARS-CoV-2 revealed that the alteration of enterocytes,
enteroendocrine and goblet cells differentiation disturb the normal intes-
tinal architecture and consequently impairs the local epithelial barrier in-
tegrity. The produced intestinal inflammation andmorphological changes
may lead in time to more pronounced cellular injuries, including the im-
pairment of oral drug absorption [102–104].
Although we do not have detailed information regarding the mech-
anisms by which the intestinal inflammation induces the over-
expression of ACE2 receptors in the GIT, it appears that modulation of
the local intestinal renin-angiotensin system (RAS) with ACE inhibitors
or receptor antagonists could attenuate inflammation and COVID-19
progression [105–107].Multiple datasets of single-cell RNA-seq analysis
indicated that SARS-CoV-2 infection of the GIT, by altering the levels of
ACE2 at the brush border, may causemicrobial dysbiosis and inflamma-
tion with important implications for oral drug absorption [108].296High ACE2 expression in cholangiocytes and to a lesser extent in he-
patocytes also suggests possible hepatobiliary infection by SARS-CoV-2
[109]. Current data evidenced that the SARS-CoV-2 infection may also
be accompanied by mild to severe hepatic damage, resulting in in-
creased activity of liver enzymes, higher serum bilirubin levels, and
microvesicular steatosis. Hence, the COVID19-dysregulation of the
liver function may add to the impact of the coronavirus disease on
drug PK [110,111].
Hence, fundamental research is required to examine the full extent
of GIT and liver aspects of COVID-19. In this regard, studies on cultures
of intestinal epithelial cells and hepatocytes exposed to SARS-Co-V2 in-
fection may be models to study SARS-CoV-2 infectivity and replication.
In order to explore drug administration systems that offer distinct ad-
vantages for oral drug administration, it would be of great interest to
understand whether and how the epithelium barrier integrity is
disrupted, as well as the degree of liver and biliary injury in patients
with COVID 19, and their impact on drug absorption.
3. Regional differences
3.1. Introduction and scope
Studies on oral drug absorption typically focus on theupper small in-
testine, as this is the first major absorptive site a drug encounters. How-
ever, it is becoming increasingly apparent that the lower parts of the GIT
also play an important role in the overall drug absorption process. In
particular, there is a renewed interest from pharmaceutical industry in
the ileum and colon as potential sites for drug delivery. However, im-
portant knowledge gaps remain on the number and function of drug
transporters in the ileumand colon, on the composition of colonicfluids,
on the drug uptake and permeation process, as well as on the in silico
modeling of colonic absorption. These knowledge gaps and recent prog-
ress in the area will be addressed in the following paragraphs.
Another aspect of oral absorption research, which is frequently
overlooked, is the role of intestinal metabolizing enzymes and the inter-
playwith systemicmetabolism: the current state-of-the-art and contro-
versies in this area will also be discussed below. Finally, the potential of
the lymphatic system as a drug delivery route after oral administration
of drugs, including viable approaches to access it, as well as intriguing
questions that remain to be answered, is described at the end of the sec-
tion. Themain gaps and the proposedway forward to gain better under-
standing of the regional differences in oral absorption research are
summarized in Fig. 4.
3.2. Targeting of oral drugs to the lower intestine and colonic drug
absorption
Although oral drug products from which the drug is, at least partly,
absorbed from the colon are available for many years, drug targeting
Fig. 3. The most important intestinal cytochrome P450 enzymes and their relative
expression in comparison with the total cytochrome P450 pool.
Data taken from [130].
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tion are associated with various challenges relating to the formulation
and/or the drug.
Products that target the lower intestine are primarily intended for
local action. Performance of relevant products has used physiological
cues such as higher pH values in the lumen of lower intestine compared
with those in the lumen of upper GIT and/or on the unique metabolism
of the bacterial flora of the lower intestine. However, the natural or
disease-related variability in pH and microbial levels can result in un-
controlled or variable release. For example, the pH in the proximal
colon of healthy adults may not be as high as in the distal ileum and it
can be much lower in the cecum [112]. Moreover, a mass movement
may empty the caecum, reducing the bacterial content as freshmaterial
enters from the small intestine [113]. Available in vitro (or in silico) tools
for evaluating the performance of drug products in the lower intestine
and/or the absorption potential of the drug from this region are vali-
dated only for the healthy adult situation [95,114].
On the other hand, the bacterial content in the lower intestine
rises gradually from the distal ileum to the caecum, and enzymatic ac-
tivity is highly variable both between and within subjects. Currently,
evaluation of the impact of bacterial drug degradation on drug prod-
uct or drug performance relies on data collected by using faecalFig. 4. Regional differ
297material (not always collected from humans). The clinical relevance
of bacterial drug degradation in the lower intestine and methodologi-
cal issues related to the human faecal material preparation protocol
has been recently addressed [115]. Despite this progress, the proce-
dure for evaluating BE of drug products targeted at the lower intestine
is not as straightforward as for conventional drugs that act or are
absorbed in the upper GIT. Depending on whether measurements of
systemic levels are possible, BE of colon-targeted drugs is evaluated
with PK studies and in vitro tests or with clinical or pharmacodynamic
(PD) equivalence studies [116].
Imaging techniques or direct sampling procedures could be useful in
understanding colonic drug disposition, but they are both associated
with certain shortcomings. Imaging provides quantitative information
only for a limited number of factors, such as the volume of free water
[20] andfluids ultrastructure [117]. Direct collection of luminal contents
from the colon is more difficult than from the upper GIT [26], because of
issues with multiple sampling and alteration of normal physiological
conditions. However, colonic content samples and tissue are useful for
the assessment of luminal conditions in various populations, bacterial
drug degradation and transporter/enzyme expression in the colonic
mucosa [26].
3.3. Prediction of colonic absorption and physiologically based pharmacoki-
netic models
For compounds intended to act systemically, extended release (ER)
formulations are commonly pursued in clinical development to
overcome dosing limitations due to short half-life and thus allow less
frequent, ideally once-daily administration, or to blunt the peak-to-
trough ratio to mitigate unwanted side-effects associated with Cmax.
For an ER formulation to fully capitalize on potential, and especially if
once-daily administration is targeted, extensive absorption from the
colon over a prolonged period is a prerequisite.
Currently, in a development setting, a priori prediction of colonic ab-
sorption is very difficult [118]. Clinical assessment of regional absorp-
tion requires the execution of complex regional dosing studies using
specialized dosing capsules [119–121] that add to the timeline and
cost of drug development; often a solution needs to be dosed thus
allowing only for studying the permeation component of the colonic ab-
sorption and not the solubility/dissolution. Alternatively, dosing of
modified release formulations and retrospective evaluation of the co-
lonic absorption in silico (e.g. via deconvolution) is pursued. However,ences summary.
Table 2
Relative expression of human xenobiotic metabolizing enzymes of CYP1, 2 and 3 subfam-
ilies, key phase II enzymes and nuclear receptors/transcription factors in small intestine at












Phase I enzymes (liver expression)
CYP1A1 + n.d.a; 0.06–2.3b n.d.
CYP1A2 − n.d.a; 0.01–0.05b 19 ± 3a
CYP1B1 n.a. n.d.a; 0.06–0.12b n.d.
CYP2A6 − n.a. n.a.
CYP2B6 ++/+ n.d.a 10 ± 2a
CYP2C8 + n.d.a 47 ± 3a
CYP2C9 ++ 4–8.2a; 1–6b 152 ± 22a
CYP2C19 ++ 0.7–1.7a; 0.15–0.84b 5 ± 1a
CYP2D6 ++/+ 0.3–0.5a; 0.85–6.1b 12 ± 1.5a
CYP2E1 ++/+ n.d.a 103 ± 7a





0.4–0.7a; 0.24–4.7b 4.7 ± 0.3a
CYP3A7 +/− n.d.a; 2.3 ± 1.5a n.a.
CYP4F2 n.a. 2.8–10.7a 20 ± 1a
Phase II enzymes
UGT1A1 ++ UGT1A1 (5.5–18.5)b n.a.
UGT1A3, 1A6, 1A9 + UGT1A6 (0.62–3.26)b
UGT1A5, 1A7, 1A8, 1A10 +++
UGT2B4 − n.a. n.a.
UGT2B7 ++
UGT2B15 +
SULT1B1, 1A3, 1A1, 1E1 +++ n.a. n.a.




PXR (NR1I2) ++ n.a. n.a.
CAR (NR1I3) +/− n.a. n.a.
AhR (AHR) + n.a. n.a.
+++=high expression;++=moderate expression;+= low expression;−=unde-
tectable expression; +/− = controversial expression or reports. Data in the table were
adapted from papers by [133,135,143,152,165,166]. n.a. – not available; n.d. – not
detectable.
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tion for BCS class 2 or 4 compounds may be difficult to separate.
While preclinical studies can be executed in different species, there
are questions on translation of preclinical to clinical data, especially
when considering the physiology differences along the GIT.
The increased utilization of PBPK models to facilitate absorption
characterization and formulation development [122], raises the ques-
tion on the readiness of application of these models to ER formulations.
While examples of applications have been published, prediction of co-
lonic absorption via PBPK models remains challenging and quite often
the current “default” models over-predict absorption and model fitting
is required to achieve acceptable predictions and establish in vitro-in
vivo correlations [123–126]. It has been proposed that correction of
the available water volume for absorption may at least partially explain
this discrepancy [127] for poorly soluble compounds. While preclinical
studies can be executed in different species to estimate regional absorp-
tion via a PBPKmodel, there are very limited reports of translation of the
models from preclinical species to humans [128]. These uncertainties
also limit application of these models in a regulatory setting as
highlighted during an FDA public workshop where “the lack of in vivo
data on the dissolution of drug products in the GIT, and local permeabil-
ity in the GIT” were highlighted as major information gaps [122,129].
Future research should focus on addressing these knowledge gaps
with the aim of developing an optimal translational strategy for predic-
tion of colonic absorption and incorporation in PBPKmodels. Thiswould
require the retrospective application of PBPKmodels to publishedmod-
ified release formulation data across BCS classes utilizing different in-
puts (e.g. preclinical data, in vitro dissolution data, in vitro
permeability data). Standardization of dissolution methodologies for
ER drug products or high dose instant-release products for poorly solu-
ble drugs and standardization of colonic permeability predictions using
in vitro or in silico approaches as proposed by Olivares-Morales and col-
leagues would help drive a more uniform approach to the models and
eventually allow for development of best practices [128]. It is antici-
pated that improving the robustness of colonic absorption predictions
will not only facilitate wider adoption of these models in drug product
development but would also provide a path to application of these
models for regulatory purposes, addressing the concerns previously
raised by regulators.a Commercially available human intestine microsomes or human liver microsomes
[167].
b Human jejunal tissues excised from morbidly obese subjects during gastric bypass
surgery [168].
c Expression of CYP3A in duodenal versus jejunal microsomes [131].3.4. Intestinal drug-metabolizing enzymes
Human small intestine epithelial cells (enterocytes) and luminal
fluids are the first site, where drug metabolism of orally ingested xeno-
biotics takes place. CYP3A and CYP2C9 are the most abundant cyto-
chrome P450 (CYPs) in the intestinal CYP pool, accounting for
approximately 80 and up to 15% of total CYP content, respectively
(Fig. 3) [130]. CYP3A4 and CYP3A5, localized on the villous tips, have
their highest expression in the duodenum and the proximal jejunum,
and the expression decreases along the human GIT [131,132].
Some members of the uridine 5′-diphospho-glucuronosyltransfer-
ase (UDP- glucuronosyltransferase, UGT) superfamily and some
sulfotransferases (SULTs) are among the most expressed phase II en-
zymes in the intestine (Table 2) [133,134]. The highest levels of UGTs
are localized in the proximal gut and decline further to the distal parts
of intestine.
Itwas shown that the small intestinemetabolismby CYP3Aenzymes
contributes to thefirst-passmetabolismofmany drugs eliminated dom-
inantly by CYP3A4 such as cyclosporine, verapamil, felodipine, midazo-
lam, tacrolimus, simvastatin or nifedipine and the effect can be
augmented by inducers (such as rifampicin) [135–142], see review by
[143]. Confirmation of the intestine as an important site of the first-
pass metabolism is mainly based on data from patients undergoing
the anhepatic phase of liver transplantation or with porto-caval anasto-
mosis [144–146], from patients with bariatric or gastric bypass surgery,298gastrointestinal intubation or in situ perfusion of human intestine
[147,148], see review [149].
Importantly, the clinical significance of the intestinal metabolic bar-
rier as a site of drug-drug interactions (DDI) or food-drug interactions
has also emerged [149]. Several juice beverages appeared to alter intes-
tinal metabolism leading to enhanced absorption [150]. Grapefruit juice
which contains significant amounts of the furanocoumarins 6′,7′-
dihydrobergamottin and bergamottin has been demonstrated as clini-
cally relevant inhibitor of intestinal CYP3A4 in metabolism of orally
ingested drugs such as midazolam [151].
“Xenobiotic” receptors such as pregnane X (PXR), constitutive
androstane receptor (CAR) or by aryl hydrocarbon receptor (AhR)
play a prominent regulating role for many drug-metabolizing enzymes
[152]. Hepatic and intestinal CYPs gene expression regulated by PXR li-
gands seems to vary both in animals and humans [136]. Importantly,
most clinical or animal data suggest that CYP3A4 orthologues induction
in the intestine is absent or significantly lower than that of hepatic
CYP3A4 expression in the liver [153–156]. Similarly, other PXR target
genes such as CYP2C8 and CYP2C9 have lower inducibility by PXR li-
gands in human enterocytes compared to the liver [153].
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intestinal metabolism for overall body clearance [157]. For many drugs
eliminated by CYP metabolism, it remains unclear whether the gut me-
tabolism could contribute significantly to thewhole-body clearance or if
it affects drug absorption. Even though the content of CYP3A4 protein
and its enzymatic activity in human enterocytes isolated from human
duodenal or jejunal mucosa is comparable to that in the liver tissue
(Table 2), the total intestinal content of CYP3A4 is only about 1% com-
pared to the total CYP3A4 content in the liver [143,158].
Several Physiologically Based Pharmacokinetic (PBPK) models have
been developed in the last years to estimate the intestinal first-pass
(or CYP3A-mediated) metabolism or the intestinal availability for
many compounds [149,159,160]. In addition, these models allowed to
predict the first-pass metabolism in DDI, study induction of intestinal
drug-metabolizing enzymes, examine the role of drug metabolism and
drug transporters along the gut ormodel presystemicmetabolism in pe-
diatric population, see reviews [149,159,161]. PBPK modeling has more
clearly established that intestinal metabolism plays a minor role in sys-
temic but not first pass metabolism. In addition, these models are used
in regulatory decisions with predictions of both systemic and first pass
metabolism, and intestinal availability nowadays [162,163].
High variability in expression has been reported for CYP3A4 and
CYP2C9 (17-fold and 9-fold, respectively) in the human intestine
[143]. This may result in significant inter-individual variability in ab-
sorption and therapeutic response. Unfortunately, there are no bio-
markers or other tools how to predict intestinal metabolism in human
personalized pharmacotherapy so far. More knowledge regarding the
role of intestinal metabolism in the first-pass metabolism as well as in
the total body clearance in humans could give us leads for future phar-
macogenetic clinical studies examining polymorphic variants of intesti-
nal drug-metabolizing enzymes in “poor metabolizer” individuals.
And vice versa, little is known about the effect of genetic variabil-
ity (single nucleotide polymorphisms, SNP) of intestinal drug-
metabolizing enzymes on drug absorption. A SNP such as CYP3A5*3
allele which results in a frameshift and truncation of CYP3A5 enzyme
significantly contributes to the total CYP3A activity in the liver and in-
testinal mucosa [152,164]. Proper understanding of the phenomenon
may help us design (i) better formulations to optimize drug intestinal
absorption independently of drug-metabolizing enzymes' genetic
variability in personalized pharmacotherapy and (ii) avoid drug-
drug or food-drug interactions during the intestinal absorption.
3.5. The role of lymphatic transport in oral drug delivery
After oral administration and absorption into the enterocytes that
line the GIT, the vast majority of drugs (and nutrients) pass into the
blood capillaries that drain the intestinal villi and from there are
transported via the hepatic portal vein through the liver to the systemic
circulation. However, an alternate transport pathway exists in parallel –
the intestinal lymphatic system. This originates as a single lymphatic
capillary or lacteal in the centre of the villi that drains into the mesen-
teric lymph and via themesenteric lymph nodes directly to the systemic
circulation. This route of transport effectively by-passes first pass me-
tabolism in the liver. The intestinal lymph is the pathway by which
themajority of dietary lipids are transported to the systemic circulation
in the form of lipoproteins and is also themajor conduit for the delivery
of GIT antigens and antigen presenting cells to the mesenteric lymph
node. In this way it provides both an alternate delivery route to the sys-
temic circulation and a specific pathway to themesenteric lymph nodes
[169,170]. The latter plays a significant gatekeeper role in controlling
immune or tolerance responses to food components and GIT antigens.
Based on data obtained in (mostly) rats, it is clear that some highly lipo-
philic drugs associate with lipoproteins and gain access to the intestinal
lymph. This is typically observed for drugs with very high lipophilicity
(typically log D > 5 and lipid solubility > 50 mg/g) [171,172] and299lymphatic transport is enhanced for more lipophilic drug analogues or
prodrugs [173–175]. Since association with lipoproteins is a critical as-
pect of lymphatic drug transport, co-administration with lipids and
food enhances lymphatic drug transport. For a very limited number of
drugs, data has been generated in multiple pre-clinical species e.g.
mouse, rat and dog and in general trends in lymphatic transport are pre-
served across species and if anything become more prevalent in higher
order species [176]. However, there is almost no data for drug transport
into the intestinal lymph in humans, since the methods employed to
cannulate lymphatic vessels are highly invasive. As such the relevance
to human drug absorption and bioavailability remains unknown. The
complexity of measuring lymph levels directly and the need for com-
plex surgical models to achieve this has also led to efforts to use surro-
gatemeasurements to estimate lymphatic transport. Themost common
of these is either measuring drug concentrations in lymph nodes or the
conduct of bioavailability studies in the presence and absence of com-
pounds such as cycloheximide that block lipoprotein (chylomicron) for-
mation [177]. Both methods are controversial, however, as increased
lymph node exposure could occur via drug transport to lymph nodes
in the blood or after association with lymphocytes in the blood, and
most chylomicron blockers are relatively non-specific and likely inter-
rupt other processes in the drug absorption chain. A decrease in oral
drug exposure in the presence of cycloheximide, might therefore reflect
a reduction in lymph transport, but may also reflect inhibition of other
absorption processes. A further controversy is whether or not stimulat-
ing lymphatic drug transport actually increases drug absorption. Most
workers in the field regard lymphatic transport as a post-absorptive
event hence we refer to lymphatic transport rather than lymphatic ab-
sorption. Thus, drugs are not absorbed directly into the lymph, but in-
stead are absorbed across the apical membrane of the enterocyte in a
similar manner to other drugs, but from there may associate with lipo-
proteins and enter the lymph. As such the simple answer to thequestion
of drug absorption and lymph transport would be to suggest that “No,
increasing lymph transport does not increase drug absorption”. However,
it is possible that improved lymphatic absorption may provide an en-
hanced absorption ‘sink’ for these highly lipophilic compounds and in
this way actually increase absorptive flux. To this point there is little
clear data to prove this since almost all methods to increase lymph
transport (dosing with lipids) also change luminal conditions and may
therefore affect absorption. This is especially the case for the highly lipo-
philic drugs that are likely to be lymphatically transported since absorp-
tion is usually solubility and/or dissolution limited and therefore highly
susceptible to changes in drug solubilization in the GIT [178].
There are many critical knowledge gaps in this field, ranging from
the fundamental to the more applied. For example, we know very little
about the process of drug association with lipoproteins. It seems to be
favoured by highly lipophilic drugs and so the assumption has been
that this is a passive ‘partitioning’ event. However, it is entirely possible
that binding proteins and transporters are involved in shuttling drugs to
the endoplasmic reticulum where lipoprotein assembly occurs or in
moving drugs across membranes. Similarly, the mechanisms by which
lipoproteins access lymphatic capillaries in the GIT is also incompletely
understood. We do know a good deal about lymphatic capillary struc-
ture [179] and it is clear that in general lymphatic capillaries are more
permeable that the equivalent blood capillaries. This provides one ex-
planation for the ability of colloidal lipoproteins to enter lymph vessels
preferentially when compared to blood vessels. But whether this pro-
cess is entirely passive and paracellular or whether active transcellular
mechanisms [180] are involved has not been shown unequivocally in
mesenteric lymphatics. As described above the anatomy of the GIT lym-
phatics is such that first pass metabolism in the liver is entirely avoided
by drugs that pass from the intestine to the systemic circulation via the
lymph. What is less clear, is whether drug association with lipoproteins
in the enterocyte may also avoid enterocyte-based metabolism. Finally,
themesenteric lymph flows firstly to themesenteric lymphnode before
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there emptying into the systemic circulation. But what are the implica-
tions of this? The potential for this to provide advantage in targeting im-
munomodulators to the mesenteric node has been explored
[175,181,182], but the amount of data generated so far is limited and
does not exist in humans.
There are a number of key directions of research progression that are
required to better understand the role of intestinal lymphatic transport
on drug absorption. First and foremost there is a critical need to gener-
ate more lymphatic drug transport data in humans. This remains chal-
lenging, but somewhat less invasive surgical approaches to lymphatic
access may provide a route to generating at least small data sets. Simi-
larly, increases in label free visualization approaches may increase our
ability to better understand intracellular trafficking. This is currently
limited by the need to use fluorophores that typically change drug prop-
erties and the appreciation that optical microscopy methods still strug-
gle to generate resolution sufficient to isolate one side of a membrane
from the other. A number of studies have sought to progress in silico
(and other) methods of prediction of lymphatic transport and have
met with some success [183–185], however the relatively small data
set of high quality lymph transport data and the lack of deep under-
standing of the mechanisms of lymphatic access have limited both cor-
relative and fundamental approaches to building lymphatic transport
models. Finally, with increasing interest in the oral delivery of larger
molecules that sit outside traditional rule-of-5 space, there is essentially
no data to provide a guide as to whether these types of molecules will
access the intestinal lymph in a similar way to relatively lower molecu-
lar weight drugs.4. Advanced formulations
4.1. Introduction and scope
The new drug candidates emerging from the drug discovery pipe-
lines of the modern pharmaceutical industry frequently display poor
biopharmaceutical properties, which limit their oral drug delivery.
Whether classical small molecules with very low aqueous solubility, or
poorly permeable and fragile biologicals, these drugs require the devel-
opment of tailored advanced formulations to allow successfulFig. 5. Advanced formulations for oral delivery
300translation to the clinic and the pharmaceutical market. In the following
paragraphs, key questions in technologies such as lipid-based drug de-
livery systems (LbDDS) and amorphous solid dispersions (ASD) are de-
bated in view of their application for the delivery of small
pharmaceutical molecules. Afterwards, the current advances and con-
troversies in oral delivery of nucleic acids and peptides are described.
The main gaps and the proposed way forward in the research of ad-
vanced oral formulations for small molecules and biologicals are sum-
marized in Figs. 5 and 7, respectively.4.2. Poorly water-soluble drugs
4.2.1. Understanding lipid-based drug delivery systems for increasing ab-
sorption and reducing food effects
LbDDS are classically used as an enabling technology to increase the
oral bioavailability of poorly water-soluble drugs (PWSD) with
solvation-limited solubility that restricts their intestinal absorption [5].
Between the different LbDDS, especially self-nanoemulsifying drug de-
livery systems (SNEDDS) have shown to be efficient. SNEDDS are isotro-
pic mixtures of oils, hydrophilic and lipophilic surfactants, sometimes
also containing a co-solvent. SNEDDS spontaneously from
nanoemulsion droplets upon dispersion in an aqueous phase, e.g. the
GIT fluids. The feasibility of LbDDS technology is well proven as more
than 150 such drug products are currently on the market [4].
Despite the fact that the LbDDS technology is widely used in drug
products and is widely researched by academics, the exact mechanism
by which LbDDS improve drug absorption is still controversial.
The digestibility of LbDDS is well characterized and documented
with regard to colloid formation and potential drug precipitation in
the case of PWSDs. However, the relation between in vitro solubilization
and in vivo exposure is not straightforward for some PWSD [186].
Existing in vitro lipolysis models, which simulate lipid digestion and
drug solubilization in the GIT, often show lack of correlationwith subse-
quent animal exposure studies [187]. This canbe due to lack of including
a gastric step, not simulating the intestinal physiology of the test animal
[12], or lack of an absorptive step in the model [188,189].
An important question for the understanding of drug absorption
from LbDDS is whether enzymatic hydrolysis of the lipid excipients is
needed for drug absorption. Some researchers clearly advocate forof poorly water-soluble drugs summary.
Fig. 6. The benefits versus the risks associatedwith the development of an oral product for
delivery of therapeutic nucleic acids.
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ing capacity, so the drug does not necessarily need to be dissolved in the
LbDDS pre-concentrate [190,191]. As amatter of fact, the digested lipids
can sometimes enhance the absorption of drug dosed as suspension in
LbDDS [192]. However, absorption from LbDDS suspensions seems to
be drug dependent, as other studies have shown reduced absorption
from these formulations [12,192,193]. This is most likely related to the
interplay between rate of drug solubilization in the digesting LbDDS
and the rate of absorption.
Industry would generally prefer digestible formulations to avoid ad-
verse effects and potential accumulation of non-degradable excipients.
Two recent PK studies, dosing halofantrine [194] and fenofibrate [193]
dissolved in SNEDDS and dosed orally to rats, investigated the effect of
incorporating orlistat, a lipase inhibitor, into the SNEDDS on the absorp-
tion of the drugs. For none of the drugs, a difference in the drug absorp-
tion was seen, but for both a change in the PK plasma curve, towards a
later Tmax when orlistat was added, was observed.
The general applicability of LbDDS is limited by the low solubility of
many drugs in LbDDS, resulting in unacceptably high excipient-to-drug
dose ratios. One approach to solve this problem is the formation of lipo-
philic salts or ionic liquids by pairing weakly acidic or basic drugs with
non-traditional lipophilic counterions. This has been shown to signifi-
cantly enhance lipid solubility and to facilitate the beneficial effects of
SNEDDS in vivo at high drug dose [195,196]. Another approach to the
challenge of low lipid solubility in LbDDS is the concept of generating
supersaturated drug concentrations in SNEDDS (superSNEDDS). The
degree of supersaturation that can be reached, and the stability that is
achieved, is dependent on both the drugproperties and the composition
of the SNEDDS. It has been shown that halofantrine was stable for at
least six months, whereas fenofibrate can only maintain a supersatu-
rated concentration for days [197,198]. The superSNEDDS concept has
been tested in PK studies in dogs, pigs and rats [12,193,194,199]. In all
cases, the drug absorption from the superSNEDDS was equal or higher
compared to conventional SNEDDS, indicating the supersaturated con-
centrations in the formed emulsions may play a role for absorption.
Recent studies have also suggested that one of the inherent advan-
tages of LbDDS may be the ability to promote in situ drug supersatura-
tion in the intestine as the formulation is dispersed and digested301[200,201]. This effect may be further enhanced by the addition of excip-
ients, such as polymers that inhibit drug precipitation [202,203].
Finally, some studies have shown that LbDDS canmitigate foodeffects,
probably depending on the colloidal phases they form upon dispersion.
Sandimmune® and Neoral® are good examples of commercial LbDDS,
both containing cyclosporin A. Sandimmune® forms a crude emulsion
and has a rather large food effect, while the subsequently developed
Neoral® is a SNEDDS that forms nanometer size emulsion droplets has
a reduced food effect [204]. In accordance, a recent study also found
that dosing a PWSD in SNEDDS resulted in a reduced food effect in
human volunteers [199,205]. However, very few studies have investi-
gated the mechanism by which the food effect is limited.
There is clearly a need to bridge the knowledge accumulated in ma-
terial and formulation sciences and biopharmaceutics to discriminate
the impact of digestion on drug solubilization/protection/absorption in
a dynamic environment. On one hand, the study of colloids and phase
transitions in vitro is generally performed with pH-stat equipment
[206] that can be coupled with various techniques [207], such as small
angle X-ray scattering (SAXS) or Taylor Dispersion equipment. Addition
of some lipid-based excipients [208,209] can critically modify the type
of colloids generated during the lipolysis with potential impact on the
drug solubilization.
On the other hand, the impact of digestion on in vitro drug solubili-
zation in colloids for absorption (eventually creating supersaturation)
is generally performed separately in pH-stat equipment only [188] or
more recently coupled to a membrane (cell-based, tissue or synthetic)
in order to favor the concurrent absorption of drug during the digestion
process [189,210]. This recent improvement of the system could favor a
better in vivo-in vitro relationship.
However, there are still very few studies looking systematically to
the role of colloid formation/transition during digestion on drug solubi-
lization, protection and absorption. Also, comparison between pub-
lished studies is not possible as very different drugs/formulations/
protocols are used.
Based on the above, the identified gaps within LbDDS development
are:
- How can in vitro lipolysis models be improved to actually be in vivo
predictive?
- What is themechanism of absorption from SNEDDS; how important
is digestion/lipolysis of the lipid excipients, and what role does the
formed colloidal phases play?
- What is the role of supersaturation in SNEDDS and what are the
mechanisms of the increased absorption?
- To what extent can SNEDDS eliminate a food effect – and which
composition is best?
To close these gaps, which will translate into better LbDDS on the
market, it is needed to develop and standardize in vitro models that
can predict the in vivo performance of LbDDS. Thesemodels should con-
sider both the media composition, the rate and extent of digestion, the
colloidal phases formed and the absorption of the drug. Different
in vitro models will be needed, depending on the drug in question, the
LbDDS to be developed (e.g.digestible vsnon-digestible LbDDS, drug so-
lution vs drug suspension) and the in vivo model (e.g. fed or fasted,
humans or pre-clinical animal models).
4.2.2. Understanding the in vivo performance of amorphous solid
dispersions
4.2.2.1. Impact of supersaturation and precipitation on drug absorption.
Among advanced formulations, ASDs represent the most commonly
used solid formulation approach [211]. To facilitate the development
of such formulations, in vitro tools that allow accurate predictions of
the in vivo behavior, as a function of formulation composition, would
be highly desirable. This is especially true with the increased interest
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pill burden, which can become an issue for high dose compounds, or to
accommodate development of fixed dose combinations. The primary
driver for the bioavailability enhancement of ASDs is the increase in sol-
ubility of the amorphous form over the crystalline drug. Thus, in vitro
tools employed to study ASDs primarily focus on characterization of su-
persaturation by studying initial dissolution (spring) and precipitation
(parachute) effects. Two of the common assays employed include (i) a
precipitation inhibition assessment to identify suitable excipients
which have the potential to maintain supersaturation and inhibit pre-
cipitation of drug candidates [212] and (ii) a two-stage dissolution
methodmimicking the pH shift between the pH in the stomach and du-
odenum in a USP2 apparatus using biorelevant dissolutionmedia [213].
If necessary, additional experiments can be conducted (i) using physio-
logically relevant ratios between the amount of ASD and volumes of dis-
solution media and (ii) evaluating the effects of crystalline material on
supersaturation and precipitation. Information obtained with these
models is typically used in PBPK modeling to bridge to the in vivo
situation.
Although a range of tools are used to develop and evaluate ASDs and
these have been successfully implemented at later stages of develop-
ment, a thorough understanding of the interaction between the drug,
polymer and physiology and its effect on dissolution and overall perfor-
mance in vivo is still missing. The composition of ASDs should result in a
good spring (i.e. fast initial dissolution to the amorphous solubility
limit) and parachute (i.e.maintained supersaturation and precipitation
inhibition) effect [214]. However, these effects are difficult to predict
and seem to highly depend on ASD composition (i.e. glass transition
temperatures of drugs, the type of polymer used and drug load). More-
over, the growing interest in high drug loadASDs can further complicate
this composition as these loads can increase the risk of poor wettability
and slow dissolution by mechanisms not related directly to the amor-
phous supersaturation (e.g. affecting tablet disintegration/erosion). In
an industry setting, screening of different ASD compositions for in vivo
performance maintains a significant empirical component with in vivo
(preclinical and ultimately clinical) studies serving as stage-gates for
decision making. More focus on linking performance to formulation
composition could have a significant impact on improving future for-
mulation screening practices. To understand how to optimize ASD com-
positions, a broad range of polymer types, polymer molecular weight
fractions, drug/polymer ratios and ternarymixtures need to be screened
and evaluated in a toolbox of assays. For example, dissolution and pre-
cipitation assays thatmimicmore closely GIT conditions (transfer disso-
lution systems) and include the solid-state characterization of residual
solids in the experiments might be needed. Additional more complex
measurements that look at the impact of amorphization/crystallization
and supersaturation on membrane flux should be considered. In addi-
tion, new developments in the spectroscopic field should be imple-
mented to allow for more systematic solid-state characterization of
non-dissolved residues [215,216]. Systematic generation of such
datasets and improved in vitro - in vivo correlation can lead to better po-
sitioning of the different screens in the development process. Further-
more, this will provide “validation” of the predictive nature of in vitro
testing, hence clearing the path to reduce the empirical in vivo
screening.
4.2.2.2. Role of nanoparticle formation during ASD dissolution. While the
characterization of supersaturation via dissolution/precipitation assays
that were discussed in the preceding paragraphs may be sufficient in
early development to screen a relatively wide range of formulation
compositions, it is now well documented that for some ASDs, genera-
tion of nanoparticles during dissolution (often referred to as liquid-
liquid phase separation) takes place and the size of these particles has
been shown to be composition dependent [217,218].While these nano-
particles were initially believed to serve as a source of rapidly dissolving
drug, the exact impact of nanoparticle formation in increasing302bioavailability remains unclear. More importantly, the available pub-
lished literature on the impact of the size of these nanoparticles on ab-
sorption in vivo, is very limited. Most of the previous publications have
focused on comparing micronized vs nanosized crystalline drug during
the investigation of nanocrystalline formulations. There are very few
controlled preclinical or clinical studies with different particle sizes
within the submicron range at clinically relevant doses. For example it
was recently reported that for an anacetrapib/copovidone/tocopheryl
polyethylene glycol succinate (TPGS) ASD prepared via hot melt extru-
sion, a reduction of the size of in situ generated nanoparticles from
~200 nm to ~100 nm resulted in approximately two-fold higher bio-
availability in dogs in either fasted or fed state [219].
Some authors have proposed that the bioavailability increases with
nanoparticles (crystalline or amorphous) can be explained by increases
in dissolution rate/solubility [220] while others have suggested impact
of nanoparticles through diffusion in mucus resulting in increased ap-
parent permeability [221–223]. If nanoparticle size can indeed affect
bioavailability by such mechanisms, this could have significant product
quality implications for those formulations where the resulting particle
size can be affected by variations that can be seen during routine
manufacturing conditions. Under current practices, dissolution and
not particle size measurement, is the primary quality control method.
Nevertheless, if the mechanism of bioavailability increase is not related
to dissolution, dissolution methods would need to be adapted to reflect
the impact of nanoparticle size or, perhaps more appropriately, alterna-
tive product quality control methods may need to be considered.
A review of available literature raises interesting questions regard-
ing the proposed bioavailability enhancing mechanisms. Most of the
manuscripts attempting to explain the bioavailability gains have relied
on computational arguments [222–224]. Even so, the identifiability of
parameters is a concern with current oral absorption models as estima-
tions of permeability/solubility/dissolution are confounded when it
comes to predicting the absorptive flux. Ideally, all input parameters
would be supported by experimental data including detailed dissolu-
tion rate and diffusionmeasurements, but this connection is still largely
lacking. For example, while diffusion through the unstirred water layer/
mucus has been suggested, when the diffusion of polystyrene nanopar-
ticles in mucus was measured it was estimated that particles of
20–100 nm(a size not commonly achieved in formulations)would pen-
etrate ~200 nm of mucus within an hour and the flux of larger particles
would be significantly slower [225]. The observed diffusion coefficients
are too slow to explain the usually fast absorption observed when
employing nanoparticles/solid dispersions. Additionally, while current
computational models suggest a favorable effect only for high perme-
ability (BCS class 2) compounds [224], bioavailability advantages have
been observed also for BCS class 4 compounds. This opens up the possi-
bility that additional mechanisms, whichmay not have been character-
ized or incorporated in computational models to date, may be in play.
To further advance our understanding it is clear that controlled pre-
clinical studies, preferably in larger animals that would allow dosing of
clinical formulations, and ideally clinical studies, where particle size is
purposefully varied within the submicron range, would be useful. Prep-
aration of the accompanying formulationswill need to involve thorough
characterization to ensure accurate understanding of what is dosed, in-
cluding measurements of nanoparticle dissolution rate under discrimi-
nating conditions. The increasing utilization of human intestinal
aspirate studies to facilitate biopharmaceutics characterization [226]
could provide additional insights by comparing the dissolution rate
and nanoparticle formation (especially particle sizemeasurements) be-
tween simulated intestinal fluids and in vivo conditions. On the preclin-
ical map, more detailed measurements of diffusion coefficients of
pharmaceutical product relevant nanoparticles in intestinal mucus as
well as development of imaging protocols, that would allow visualiza-
tion and quantitation of mucus associated nanoparticles after oral ad-
ministration, could provide better insight on the absorption process of
nanoparticle formulations. Finally, the incorporation of such input
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sensitivity analysis (PSA) to understand identifiability issues, would en-
able to further develop computational models and validate those
against controlled datasets.
It is envisioned that such an advancement in our understanding of
nanoparticle impacts on absorption could lead to improvements in effi-
ciency during product development. Coupled with further advance-
ments in linking dissolution of ASDs to primary formulation
composition, this can allow formore rational design of advanced formu-
lations with an understanding of the limits of bioavailability enhance-
ment, as well as a selection of the most appropriate methodologies for
quality control as already discussed earlier in this section. Collaborative
research between academic groupswith access to characterization tools
and industry partners with access to in vivo (especially clinical data) is
recommended to propel the field forward.
4.3. Biologicals
4.3.1. Introduction and scope
There are many examples where the issue of delivery of a drugwith a
specific advantageous pharmacology is hampered by the lack of an appro-
priate, tailored delivery system. The current concernwith regard to orally
administered nucleic acids and peptides is a case in point, where very low
and variable absorption has to be acceptable if such drugs are to be used.
Peptides such as desmopressin acetate are available as oral tablets, even
though the formulation has an oral bioavailability of 0.1% and food delays
and decreases absorption [227]. The drug is useful and safe, but bioavail-
abilities of this order risk huge swings in pharmacological effect if even
small increases in bioavailability are achieved by formulation, which rep-
resents a high commercial risk [228].
These less permeable drugs require innovative approaches to im-
prove absorption and there are translational difficulties moving from
animal to man [229]. Brayden and Alonso have summarized the prog-
ress in a recent editorial: synthetically produced peptides can be pro-
duced cheaply and companies are developing smaller, less hydrophilic
cyclic peptides with lipophilic motifs [230]. They also alert the audience
to the advantages of appropriately positioned delivery. If the organ pro-
ducing thehormoneof interest is situated in or near to the gutwall, then
oral delivery might be preferred from subcutaneous delivery and thatFig. 7. Advanced formulations for oral
303approach should lead to less bystander side-effects. The formulation ap-
proaches of stealthwith nanocarriers and conjugates [231,232] or phys-
ically broaching the intestinal wall are also being considered. Recently,
LbDDS have shown encouraging results for the protection of peptides
against metabolic degradation [233] and absorption in preclinical
models [234], with the non-digestible excipients/formulations sug-
gested to be key in avoiding peptide degradation [235]. The theoretical
risks of intra-oral needle-based systems and approaches using en-
hancers in order to access the systemic circulation must be considered
in the context of both the healthy and the sick gut where appropriate
models for safety assessment may be poorly developed.
These and other aspects of the contemporary approaches for oral de-
livery of nucleic acids and peptides are presented in the following
sections.
4.3.2. Oral delivery of therapeutic nucleic acids by non-viral methods
4.3.2.1. State of the art.Advances in knowledge regarding the genetic basis
of disease has opened up innovative opportunities to develop gene-based
therapies where gene silencing or upregulation is now feasible using ei-
ther siRNA or mRNA, respectively [6,236]. Although this field is still in
its infancy, progress has been made mainly using viral delivery methods
for parenteral administration. However due to significant disadvantages
associated with viral delivery, including immunogenic reactions, poor
loading capacity, scale-up and manufacturing issues, research interest in
non-viral formulations is growing apace [237,238]. In 2018, the first
ever non-viral siRNA product (Patisiran, Onpattro®) [239] using a lipid-
based nanoparticle was licensed, followed late in 2019 by licensing of a
siRNA-N-acetylgalactosamine (GalNAc) covalent conjugate (givosiran,
Givlaari®) [240], both administered parenterally to target liver disease.
The existence of these products shows the technologyworks and the
major challenges remaining are to extend the technology to other sites
beyond the liver and to non-invasive routes of administration including
oral, the advantages ofwhich arewidely known. In addition,many ther-
apeutic targets exist for oral administration of nucleic acids including
local treatment of IBD and intestinal cancers, and the potential for sys-
temic absorption to target other disease sites. Several academic groups
are already exploring oral delivery [4,241–244] and companies have
publicly declared their interest.delivery of biologicals summary.
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mercial prospect,manyunansweredquestions still remain,whichhamper
translation and delay access for patients to these life-altering therapies
(Fig. 6). Examples of these knowledge gaps are highlighted below.
4.3.2.2. Novel chemistries. The physicochemical properties of nucleic
acids including largemolecularweights, complex hydrophilic structures
and high negative charge result in poor membrane permeability and
susceptibility to enzymatic degradation, making oral delivery difficult.
However, the chemistry of RNA molecules in particular siRNA and
mRNA can be modified to improve stability and enhance efficacy and
enzymatic resistance [6,236,245]. The ability of these structural modifi-
cations to maintain stability in the gut needs to be addressed.
4.3.2.3. Site specific delivery systems. In tandem with synthesizing more
stable NA cargos, the other major gap in our knowledge is the design
and preparation of delivery systems capable of surviving the harsh envi-
ronment of the gut. These delivery systems must also possess adequate
loading and release properties which will achieve sustained and con-
trolled transfection. The site of action, either locally at the gut wall or
systemically following absorption, will influence the formulation de-
sign. Local administration will avoid the barriers faced in the circulation
and should provide research opportunities likely to yield success in a
shorter timeframe.
4.3.2.4. Will current approaches work in the gut?. To tackle the RNA deliv-
ery dilemma, two main approaches based on (1) nanoparticles [245],
(2) covalent nucleic acid conjugates have been exploredmainly for par-
enteral administration [246,247]. Nano constructs engineered with a
variety of biocompatible materials have been investigated with varying
degrees of success [236,248]. Of these materials, pH-dependent ioniz-
able lipids capable of forming lipid nanoparticles (LNPs) incorporating
nucleic acid deserve particular mention. LNPs are used to deliver
siRNA in themarketed product Patisiran (Onpattro®) and this formula-
tion approach is also used in mRNA Covid-19 vaccines by several com-
panies (NCT04368728, NCT04470427). Both products have shown
≈95% efficacy in Phase 3 trials (Nov 2020) and application for emer-
gency use authorization has been filed to the FDA [249]. Can these ap-
proaches be exploited for oral delivery?
4.3.2.5. What lipids to choose?. The most commonly used LNPs consis-
tently contain a blend of 4 lipids including an ionisable cationic lipid
(e.g. heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)
butanoate, DLin-MC3-DMA), cholesterol, distearoyl phosphatidyl cho-
line and a pegylated-lipid [250,251]. To date while the LNP approach
has mainly been successful for targeting the liver, the approach has
also been used to target other tissues including the intestine. An anti-
body targeted LNP encapsulating modified mRNA [252] increased the
expression of interleukin 10 by Ly6c+ inflammatory leukocytes in dis-
eased tissues resulting in a therapeutic benefit in an IBD animal
model, however intravenous administration was used. The challenge
of transfecting the intestine following oral administration of siRNA has
been investigated [241]. Following oral gavage, although the LNPs ap-
peared to be taken up by intestinal cells, no gene silencingwas detected.
These studies identified pepsin in the stomach and bile salts as the
main barriers limiting the transfection efficiency of the LNPs particularly
under fed state conditions. The influence of the bile salts while unclear
maybe related to solubilisation of the NP lipids causing deconstruction
of the LNP. Although extensive research is ongoing into the design and
modification of lipids [253] a detailed characterisation of the orientation
and packing of these ‘newer’ lipids within NPs is currently lacking, such
studies may help identify more stable LNPs with potentially enhanced
resistance to the influence of bile salts.
4.3.2.6. Alternative excipients combinations. Alternatively, lipids such as
those found in exosomes may help to improve the design and efficacy304of lipid-based formulations. Exosomes are a type of extracellular vesicle
of which lipids are a major component [254]. Exosomes derived from
milk have been investigated as potential oral delivery systems for mac-
romolecules including siRNA [255] and microRNA. Milk exosomes have
been shown to be resistant to digestion in the gut and have wide
biodistribution including to the brain following oral delivery [256].
However, in order to fully exploit the drug delivery potential, more
needs to be discovered regarding the biological function of these ‘natu-
ral’ lipids, in addition, challenges regarding large scale production and
consistent quality also need to be overcome.
An interesting alternative approach for future investigation in the
oral space may be the combination of the lipids described above with
newer materials including modified cyclodextrins and biocompatible
polymers [257,258]. Such combinations may enable higher loading
and increased stability in the harsh environment of the gut.
4.3.2.7. Conjugates - beyond the liver. In contrast to NPs, covalent conju-
gates of siRNA may also provide a solution to oral delivery in particular
for systemic versus local availability. The siRNA.GalNac conjugate, in
combination with a permeation enhancer was reported to produce a
dose dependent reduction in a serum biomarker post oral gavage of
siRNA conjugate [259]. While this conjugate is again targeted for liver
disease the potential exists to explore this approach for other therapeu-
tic applications beyond the liver. To enhance the stability and absorp-
tion capacity, the concept of more lipophilic conjugates capable of
self-assembly into nano-constructs, similar to that described recently,
may be an exciting future possibility [260].
4.3.2.8. Regulatory constraints. Regulatory hurdles for novel materials
used in innovative drug delivery systems, including oral products, are
a major concern for the industry. While of course safety is paramount,
translational progress is andwill be hampered if drug delivery scientists
are limited to a set list of traditionally used GRAS (generally recognized
as safe) excipients. This is a particular issue for delivery of macromole-
cules like proteins and nucleic acids where excipients are often integral
to the mechanism of action and efficacy. To help break this deadlock,
more research is urgently needed to identify the issues, explore poten-
tial solutions and develop regulatory guidelines for the use of novel ex-
cipients based on a risk-informed decision-making process.
One potential solution may be to consider a streamlined approach
and to assess and license the product as a whole (NA plus excipients)
on a case-by-case basis, in this way innovative delivery systems for
rare diseases with unmet clinical needs could reach the patient in a
timely fashion. In tandem such studies would progressively build a dos-
sier of information on the individual novel excipient while mitigating
risk by assessing its role within the product.
4.3.3. Oral peptide delivery
Peptide drugs are substantially larger than traditional drugs and can
therefore interact with promising targets that are “difficult-to-drug”
using traditional membrane permeable molecules. While peptides
offer the opportunity to expand the number of “druggable” targets,
they have well known drawbacks, including poor membrane
permeability (as the nucleic acids, described in the previous section)
and negligible oral bioavailability [261]. In the following paragraphs,
the state-of-the-art, current challenges and knowledge gaps in the var-
ious oral peptide delivery approaches will be outlined.
4.3.3.1. Transient permeation enhancers. To overcome the formidable
physiological barriers and enable oral delivery of peptides, scientists
and formulators have investigated the use of transient permeation en-
hancers (TPEs) with/without enzyme inhibitors. TPEs are compounds
that can temporarily and reversiblymodulate the permeability of the in-
testinal epithelium. Examples include sodium caprate, medium chain
glycerides and derivatives, acylated amino acids such as N-[8-(2-
hydroxybenzoyl) amino] caprylate (SNAC), acyl carnitines, bile salts
Table 3
Examples of peptide/TPE formulations that have advanced to clinical testing or registration.





Subjects No. Clinical stage Ref
Basal Insulin 338 (a long-acting,
basal insulin analogue)
Sodium caprate (GIPET I®, Merrion) Not evaluated 82–132 44 Phase II [262]
Desmopressin Mono-, diglycerides of C8 & C10 (GIPET II®, Merrion) 2.4 124 18 Phase I [263]




8 NDA accepted for
review 2015
[264]
Parathyroid hormone (PTH1-34) Acyl carnitine/citric acid (Peptelligence®, Enteris) 0.58 (week 0) 99 (week 0) 32 Phase II [265]
Octreotide Oily suspension containing sodium caprylate, glyceryl
mono- and tricaprylate (TPE®, Chiasma)
0.8 62 71 Approved, 2020 [266]
Semaglutide Acylated amino acid, SNAC (Eligen®, Emisphere) 0.4–1 65–84 11–32 (for
variability)
Approved, 2019 [267,268]
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inhibitors) has resulted in some degree of success, with a number of
peptide/TPE combinations entering clinical studies and some advancing
to late stage clinical testing and regulatory “new drug” applications and
approvals. Table 3 summarizes someof themore advanced clinical stud-
ies that have been reported in the literature using TPEs to enable oral
delivery of peptides.
Despite the progress made using TPEs to enable oral delivery of pep-
tides and the success (albeit still limited) in advancing these to clinical
studies, oral bioavailabilities are still very low (low single digit at best)
andvariability is still very high (coefficients of variation typically>50% to-
gether with dosing periods when negligible drug is absorbed). These is-
sues hinder the commercial “developability” of oral peptides (Table 3).
Hence, considerable efforts are on-going aimed at identifying better
TPEs or delivery systems to enable higher oral bioavailabilities. Notable
recent examples of TPEs include pelargonidin (a strawberry extract
component), which reportedly had impressive effects on oral bioavail-
ability of insulin yielding levels resembling or superior to those
achieved following subcutaneous administration [269] and the ionic liq-
uids based on choline and geranate reportedly yielding an oral bioavail-
ability of insulin of approximately 50% following intrajejunal
administration [270]. Building on the ionic liquids concept, lipid formu-
lations incorporating peptides hydrophobized via non-covalent interac-
tions (e.g. ion pairing, hydrogen bond pairing), are receiving increasing
attention in this area and will be described in more detail in the follow-
ing subsection.
In addition, an emerging trend is to chemically engineer peptides to
render them more suitable for oral administration. This includes modi-
fications to make the peptide more resistant to enzymatic degradation
in the GIT as well as increasing the systemic half-life of the peptide to
better accommodate variability. The latter, viz. half-life extension strat-
egies such as fatty acid-acylation of the peptide, has been a fortunate
gain from efforts being made in the parenteral space aimed at reducing
dosing frequency from daily to weekly (or longer). Having a long half-
life (>100 h), allows the high variability associated with oral delivery
of peptides to be somewhat accommodated because the resulting
drug accumulation can “keep drug onboard” even over days where no
orminimal drug is absorbed. This strategy has been adopted for the suc-
cessful development of the oral glucagon-like peptide-1 (GLP-1) recep-
tor agonist semaglutide product, Rybelsus®, approved by the FDA in
September 2019 and represents the first successful commercial oral
peptide product delivered using a TPE.
However, the success of Rybelsus® raised several questions. Can
peptide engineering be used to make peptides more amenable to for-
mulatingwith TPEs? Is promoting the interactions between the peptide
and TPE (as exemplified by SNAC that reportedly interacts with
Semaglutide to promote monomerization of the peptide and enabling
stomach absorption [271]) beneficial for all types of peptides or what
kind of interaction is optimal?305If the aspect of peptide/TPE interaction can be better understood, it
could open theway for the use of in vitromethods that can characterize
such interactions (e.g. isothermal calorimetry, nuclear magnetic reso-
nance (NMR), dynamic light scattering etc.) to be used in the selection
of the preferred TPE to combine with a particular peptide (e.g. [272]).
With an improved understanding of the preferred types of interactions,
ultimately in silico techniques such as molecular dynamic simulations
(e.g. [273,274]) could be employed to identify preferred combinations
thereby overcoming the need, or at least reducing the need for multiple
in vivo studies to screen and select peptide/TPE combinations.
Methodology issues in TPE screening should also be addressed. Typ-
ically, TPEs are screened for their suitability to promote systemic ab-
sorption of peptides by in vitro techniques such as the parallel artificial
membrane permeability assay (PAMPA), Caco2 (or similar) or Ussing
permeability assays before progressing to in vivo rodent and subse-
quently larger pre-clinical animal models. These in vitro systems lack
many of the functionalities of a “live” intestine such as the ability to re-
generate and re-model following exposure to TPEs, as well as lacking
the existence of a native 3D mucus structure; and many of the in vivo
preclinical models give overly optimistic predictions of bioavailabilities.
To advance our understanding and use of TPEs for promoting oral deliv-
ery of peptides, we need to improve and expand our “Biopharm” tool-
box such that peptide/TPE combinations can ultimately be developed
as efficiently as currently being done for small molecules. As an exam-
ple, can 3D organoids (intestine-on-a-chip) or similar be developed to
enable such screening, and simplified such that high throughput screen-
ing can be conducted on a scale similar to that done in the
“developability” assessment of small molecules [275]. Similarly, the
existing “Biopharm” toolbox would also need to be expanded to better
evaluate oral peptide technologies reliant on transporters as well as
nanoparticulate delivery systems.
The chronic use of TPEs also requires careful safety profile consider-
ations. As mentioned, TPEs increase intestinal permeability by opening
tight junctions or modifying membrane structure to allow large hydro-
philic molecules such as peptides to be absorbed. By inference, if pep-
tides can be absorbed then it is possible that other molecules usually
excluded by the intestinal epithelium can also be absorbed. Chronic
use of TPEs, as could be expected for many indications, would also
mean repeat “permeabilization” of the intestinal membrane (although
unlikely to occur to the same place in the intestine). Despite the safety
of SNAC (300 mg) being evaluated in studies with a mean duration of
~60 weeks of daily dosing to support the approval of Rybelsus® [267],
the long term safety following chronic use of other TPEs and at various
dose levels needs to be further investigated and understood.
4.3.3.2. Hydrophobic pairing as a strategy to enhance permeation. It is gen-
erally accepted that both ionic and non-ionic surfactants exhibit a per-
meation enhancing effect on the intestinal mucosa as they are
interacting with epithelial cells via different mechanisms [276].
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these permeation enhancers with the drug itself is at least as important
for an improved oral bioavailability as their interaction with the mem-
brane [277,278]. Due to the formation of hydrophobic ion pairs (HIPs)
and hydrophobic hydrogen bond pairs (HHPs) H-bond donor and H-
bond acceptor substructures on poorly permeable drugs can be masked
resulting in improved membrane permeability. According to Lipinski's
rule of 5, the number of H-bond donors has to decrease below 5 and
that of H-bond acceptors below 10 using HIPs and HHPs for such a
masking. For drugs> 500Da a log D of 3 seems advantageous to provide
high membrane permeability of such complexes [279].
Although the concept of hydrophobic ion pairing has been known
for many decades and there are numerous publications providing evi-
dence for its potential in form of in vitro permeation studies [280,281],
to the present date this potential could not be translated into an im-
proved oral bioavailability. The reason for this failure in most in vivo
studies is the poor stability of HIPs and HHPs under the harsh intestinal
conditions, as there are simply too many competitive counter ions as
well as H-bond donors and acceptors available destroying these com-
plexes on their way to the absorption membrane [277,282]. Nazir and
colleagues demonstrated that the dissociation of HIPs increases with in-
creasing salt concentrations over time. At salt concentrations equivalent
to that of GIT-fluids, half of the HIPs dissociatedwithin 4 h [282]. In case
of HHPs, in particular mucus glycoproteins bearing countless competi-
tive H-bond donor and acceptor substructures, represent an immense
threat to the stability of these complexes. Accordingly, the likelihood
that intact HIPs or HHPs reach the absorption membrane, as in the
case in well-designed in vitro permeation studies, is low.
Due to the incorporationofHIPsandHHPs in lipid-basednanocarriers
such as solid lipid nanoparticles (SLN), nanostructure lipid carriers
(NLC), o/w nanoemulsions or SNEDDS, a sufficient high stability of
these complexes can be guaranteed. As most competitive counter ions
as well as H-bond donors and acceptors are simply too hydrophilic,
they cannot penetrate into lipid-based nanocarriers in order to destroy
the incorporated HIPs and HHPs. Moreover, as the dielectric constant of
lipophilic excipients is up to 80-fold lower than that of GIT-fluids, HIPs
are even further stabilized within lipid-based nanocarriers. In case of
HHPs, competitive H-bond donor and acceptor interactions can be
avoided to a high extent by lipid-based nanocarriers comprising aprotic
and apolar excipients such as paraffins or squalene. Furthermore, by
the exclusion of lipophilic excipients exhibiting ester substructures, the
degradation of lipid-based nanocarriers by lipases can be ruled out
[235]. Once these nanocarriers have permeated themucus gel layer and
reached the absorption membrane, they are supposed to fuse with the
outer cell membrane releasing intact HIPs and HHPs.
Although our knowledge about the membrane transport of HIP/HPP
is still very limited, there are at least some studies providing evidence
[283]. Motion and colleagues demonstrated that the delivery mecha-
nism can be further improved by engineering phosphatase-triggerable
lipid-based particles displaying phospho-peptides on their surface.
After removal of the phosphate groups by membrane-bound phospha-
tases, the specific peptide can then activate membrane fusion and pro-
vide cytosolic delivery of encapsulated compounds in a highly efficient
manner [284]. An improved knowledge about this fusion process and
other likely involved mechanisms such as endocytosis will certainly be
the key to success for this emerging technology. In addition, the design
of lipid-based nanocarriers releasing their payload in a targetedmanner
directly at the absorption membrane might be another promising ap-
proach. Lipid-based nanocarriers such as o/w nanoemulsions or
SNEDDS being emulsified by a phosphorylated surfactant, for instance,
might be designed in a way that they release their payload directly at
the absorption membrane. As the phosphate group of such surfactants
is rapidly cleaved off from its lipophilic tail by the absorption
membrane-bound alkaline phosphatase [285], the surfactant loses its
emulsifying property and the oily droplets will disintegrate and liberate
HIPs and HHPs in a targeted manner. Addressing the interaction of306lipid-based nanocarriers with the absorption membrane by a
two-track strategy focusing on one hand on an improved knowledge
about their fate on the membrane and parameters controlling it and
on the other hand on the improvement of already established lipid-
based nanocarriers for HIPs and HHPs delivery is likely most straight
forward. It will open the door for more efficient oral delivery systems
especially for BCS class 3 and 4 drugs.
4.3.3.3. Epithelial transport systems and cell penetrating peptides. To avoid
having to modulate the permeability of the intestinal membrane, which
may come with associated safety concerns, or to use complex hydropho-
bic pairing strategies, researchers have also investigated the exploitation
of inherent transport systems present in the intestinal epithelium.
For example, the proton-assisted small amino acid transporter (PAT-
1/SLC36A1) was recently evaluated for the oral delivery of insulin
wherein insulin was encapsulated in zwitterionic betaine (a PAT-1 sub-
strate) polymer micelles stabilized by an unusually low critical micelle
concentration. Limited proof for the uptake mechanism was presented,
but nevertheless, cellular accumulation and systemic delivery of insulin
followed by a glucose lowering effect in diabetic rats was observed
[286]. In another example, the domain 1 of the V. cholerae toxin (cholix)
was investigated as a strategy to promote peptide absorption across the
intestinal epithelium, taking advantage of the inherent vesicular trans-
portmechanism that enables the delivery of the toxin across the epithe-
lial barrier. In this case, significant systemic levels of human growth
hormone were reported when the peptide-cholix conjugate was orally
administered, but bioavailability was not determined [287].
Conjugation with cell penetrating peptides (CPPs) is another ap-
proach that has been investigated for promoting oral drug absorption
but mechanistic information for transcellular transport has not yet
been presented at the level of e.g. cholix-mediated transcytosis [288].
Since themain uptakemechanism formembrane penetration is binding
to the cell surface followed by endocytosis, the most promising ap-
proach has been to use CPP-peptide conjugates to enhance the intracel-
lular delivery of peptides by an endosomal escape mechanism. A
particularly promising CPP that provides efficient endosomal escape
and thereby promotes intracellular target access is CPP9 [289]. For in-
stance, conjugation with this CPP enhanced the intracellular efficacy of
a variety of stapled peptides between 10 and 100-fold [290].
4.3.3.4. Nanoparticle formulations. Themultiple reasons behind theunful-
filled promise of nanoparticles for oral delivery of peptides were
unraveled in the pan-European project “TransInt” (2012–2017) and
pointed at the complexity of developing such systems to translatable
oral delivery systems [230].When challenged by preset specifications, a
lack of connection between elegant nanotechnology and realistic formu-
lation requirements, such as required peptide payload, loading efficiency
and release kineticswas revealed. Insufficient consideration of biochemi-
cal and physiological barriers in the GITwas also a problem. Examples of
biochemical shortcomings include enzymatic degradation of the peptide
or little knowledge of how the entrapment or encapsulation influence
thenativepeptideconformation.Examplesofphysiological shortcomings
include failure to overcome the various physiological barriers in the GIT
and lack of scalability to larger species. None of the nanoparticle candi-
dates were able to deliver sufficient amounts of the therapeutic peptides
to be of interest for further development. An informative summary of
the problems encountered is given in a recent review [291].
Strategies such as those developed within the TransInt consortium
however could be applied more rigorously in order to reduce efforts
on those nanoparticle formulations which have little chance of success.
Factors such as robustness, stability and batch-to-batch reproducibility
(many formulations in the TransInt consortium did not survive transfer
between laboratories and others did not give reproducible results be-
tween batches) and compatibility with the peptide of interest at
amounts predicted to give the desired systemic effect (e.g. loading ca-
pacity, maintenance of native peptide structure, protection of the
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peptide at the desired rate) can be investigated in most laboratories at
relatively low costs. Early consideration of such in vitro liabilities could
save resources by reducing the number of unnecessary studies in intes-
tinal barrier models of various complexity as well as in vivo studies.
4.3.3.5. Ingestible injectable devices. To further exemplify the interest in
oral delivery of peptides in an attempt to offer patients an alternative
to injectable parenteral administration, researchers and companies are
investigating and developing “ingestible injectable” devices, hence
moving the invasive administration site from the subcutis, which has
a high density of sensory neurons, to theGIT, which is devoid of such re-
ceptors. Examples include the self-orientingmillimeter-scale applicator
(SOMA) and luminal unfolding microneedle injector (LUMI) designed
to inject the peptide directly into the gastric or intestinal epithelium re-
spectively and reporting double digit bioavailabilities [292,293]. The
most established of these ingestible injectable technologies is the “ro-
botic” RaniPill™. Recently released details on its first Phase I trial re-
ported an oral bioavailability of octreotide greater than 70%, with an
acceptable tolerability profile [294]. Although thePhase I study reported
the administration protocol to be safe, “RealWorld” evidence of the use
of these kinds of devices needs to be generated as issues related to ob-
struction rates and injury following multiple, long term dosing needs
to be generated. It also needs to be evaluated whether the additional
cost-of-goods and the manufacturability of these “ingestible injectable”
devices can be accommodated to enable the successful clinical and com-
mercial translation of these devices.
4.3.3.6. Future outlook. Despite extensive efforts having been made over
the past 30+ years to enable oral administration of peptides, there has
been little success since the approvals of cyclosporin and desmopressin
(DDAVP, a synthetic vasopressin analogue) in the 1990s beyond a num-
ber of candidates entering late stage clinical testing (see Table 3 for ex-
amples). These candidates have almost exclusively used TPE's as the
strategy to enable systemic absorption of peptides following oral ad-
ministration, with a couple of exceptions being silica particles and the
hepatic-directed vesicle (HDV), and a lipid-nanoparticle carrier (both
in Phase II as of mid-2020). Despite this hiatus, in the last year we
have seen approval of two oral peptide products, Rybelsus®
(semaglutide; September 2019) and Mycapssa® (Octreotide; June
2020). The former, semaglutide, is an engineered peptide designed to
have a long half-life, thereby able to accommodate the high variability
associated with oral peptide delivery. It remains however to be seen
whether peptide engineering will finally enable TPEs (or indeed other
strategies described above) to be used as a routine strategy for oral pep-
tide delivery. Even if so, bioavailabilities are still likely to be very low
(low single digit) and cost of goods hence a challenge.
To overcome these limitations, recent focus has turned tomore “dis-
ruptive technologies” with the aim of achieving systemic bioavailabil-
ities similar to sub-cutaneous delivery but with the convenience of
oral administration. Notable developments in this area have included
the “ingestible injectable” devices recently appearing in high impact
journals and reporting double digit bioavailabilities [292,293] and the
report that the RaniPill™ was able to achieve 70% oral bioavailability
of octreotide whilst being well tolerated in a Phase I study. It will be in-
teresting to see the adoption of such “disruptive” technologies by both
industry and patients, and whether these innovations will ultimately
revolutionize peptide delivery.
5. In vitro and in silico tools for exploring advanced drug
formulations
5.1. Introduction and scope
Although advanced formulations are used to solve various hurdles
encountered in drug development, these benefits come at the expense307of stability issues and complex behavior in the dynamic conditions of
the GIT. Events such as supersaturation, precipitation and formulation
digestion often render classical in vitro and in silico tools inadequate
for the study or description of the fate of the drug formulation after
ingestion.
Therefore, biorelevant tools with improved capacity to predict the
in vivo behavior of such formulations are required. In the following par-
agraphs, controversies in biorelevant dissolution, permeation and com-
bined dissolution/permeation models are addressed, followed by an
update on cutting-edge analytical methods used in this context. After-
wards, a vision for the combination of in vitro, in silico and in vivo data
for the prediction of the performance of oral drugs is presented. Finally,
the current limitations and future opportunities in PBPK modeling are
discussed. The specific applications of PBPK modeling in the context of
special populations, regional differences, advanced formulations and
food-drug interactions is situated in the corresponding sections of the
paper. The main gaps and the proposed way forward in the area of bio-
pharmaceutical tools are summarized in Fig. 9.
5.2. Biorelevant dissolution testing
The development of biopredictive dissolution tests aims at realistic
simulation ofmechanical and chemical conditions of the GIT. The devel-
opment follows one of twomain strategies: complex devicesmimicking
the GIT anatomy such as the dynamic gastric model (DGM) [295], TNO-
TIM-1 [296] and tiny-TIM [297], or simple abstract models. The main
advantage of complex devices is the representation of the GIT condi-
tions by simultaneous simulation of multiple factors. Unfortunately,
these experiments are time-consuming, costly and have low through-
put. Here iswhere the simplermodels come in: although they do not re-
flect the anatomy of the GIT, they can successfully simulate individual
physiological factors via working principles and parametrization
[298,299]. Some examples are the rotating beaker apparatus [300],
BioGIT [301], bio-relevant dissolution stress tester [302], or its later
modifications such as Gastro Duo [303] and the Dynamic Open Flow-
Through Apparatus [304,305]. The devices were successfully evaluated
on numerous examples of clinical relevance [302,306–310]. Use of the
bio-predictive methods enabled effective support of the development
of dosage forms, identification of undesired drug delivery performance
of formulations, such as dose dumping or decreased availability of the
drug and checking the pharmaceutical equivalence of various products
[298,302,306,308,309,311–315].
The key issue in biopredictive evaluation is the realistic simulation of
the conditions along the GIT, especially considering the variation of the
physiologically relevant factors. Therefore, the appropriate test scenario
is as important as the device itself. The pragmatic question is what are
the truly “biorelevant” conditions to simulate? Temperature, pH gradi-
ents and pressure values along the GIT have been studied with the use
of telemetric capsules [316–318]. However, the results should be
treated with caution as the reliability of measurements might be com-
promised due to technical reasons (i.e. construction, measurement
range and size). Additionally, the results confirm high intra- and
inter-subject variability. Consequently, there cannot be a universal test
protocol covering the wide range of pH values, intensity of mechanical
agitation and passage times in one experiment. Applying average condi-
tions is not justified either as they do not reflect any of the physiological
situations. The biggest challenge to overcome is finding a way to imple-
ment the variability range of the conditions of the GIT passage into a set
of biopredictive experiments.
Another problem to solve is the simulation of GIT fluids. Commer-
cially available solutions simulating both fasted and fed state are easy
to use and provide reproducible results. However, they neither reflect
pH variability among GIT nor enable performing analysis in high-
resolution pH gradients [307,319]. It should be also noted that most dis-
solution tests are performed in unrealistic high volumes to provide sink
conditions [20]. This does not reflect the physiological conditions and
Fig. 8.Overview of the currently available permeation tools used for intestinal permeability profiling. Permeation tools are subdivided into three classes including tissue-based, cell-based
and cell-free permeation tools supplemented with their common characteristics.
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cipitation, compromising the predictability of the test [20,320,321].
As the impact of the compositional variability of GIT fluids on drug
solubility is well established [26,322], sets of multiple media defined
by a design of experiment approach have been developed to tackle the
issue [23,323].
An additional important issue is the impact of dynamic digestion and
its products on drug delivery performance, especially in case ofFig. 9. Biopharmaceutic
308lipid-based formulations [27,324]. Simple dissolution tests performed
with a single biorelevant media with a constant composition usually
do not reflect the digestion and might significantly underestimate the
delivery rate.
To our understanding the point by point simulation of every individ-
ual GIT passage via extremely complexmodels is unreasonable. It is cru-
cial to understand the interplay between the working principles of the
formulation and GIT conditions to determine rate-limiting conditions.al tools summary.
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evaluate the influence of individual physiological factors, simulated as a
set of consecutive experiments. Careful selection of proper dissolution
setup from a pool of various tests should be based on their usability
range and limitations. The problem of high variability of the GIT transit
can be overcome by covering the boundary conditions (e.g. the 25th and
75th percentile) of pH gradients, intensity of mechanical stress agita-
tion, time of passage, etc. It would lead to determination of the variabil-
ity range of the drug delivery performance that might be expected
in vivo.
Finally, the challenging goal of truly bio-predictive dissolution test-
ing can be achieved only by integration of advanced techniques and
pragmatic interpretation of the outcomes.
5.3. Permeation models
In combination with solubility, permeability is a key parameter dic-
tating intestinal drug absorption following oral administration, and as a
result should be carefully explored during early phases of drug
discovery and development. As illustrated in Fig. 8, a diversity of well-
established in vitro permeation tools is available to obtain a first estima-
tion of intestinal permeability, including cell-based, tissue-based and
cell-free models. Comprehensive information on the advantages and
limitations of the different approaches is available in dedicated reviews
[325–327].
Most of the developed permeation tools result in a good estimation
of the rank order of human intestinal permeability, however, the out-
come is highly affected by the experimental test design [328]. Extensive
efforts have been made to demonstrate the importance of selecting the
appropriate media in the donor and acceptor compartment in order to
maximize drug recovery and consequently, offering improved reliability
of the apparent permeability results [329,330]. For instance, pharma-
ceutical companies typically use apparent permeability coefficients ob-
tained in cell-based (Caco-2, MDCK, LLC-PK etc.) assays to support their
drug development programs. However, these cell-based permeation
tools are not advised to be implemented as a permeation compartment
in in vitro dissolution models for the evaluation of absorption-enabling
formulation strategies given their (i) moderate throughput, (ii) lengthy
and cost-consumingpreparation steps and (iii) limited compatibility to-
wards solubilizing pharmaceutical excipients and food components.
Cell-free permeation barriers are considered as attractive alternatives
to be used in combined dissolution/permeation tools for assessing for-
mulation performance, as these artificial membranes are compatible
to biorelevant media, easily resist pharmaceutical excipients, food com-
ponents and a wide range of pHs [14]. Unfortunately, only a limited
number of case examples are described in literature implying that
more efforts are needed before the full potential of these combined dis-
solution/permeation systems could be achieved. Particularly for the
evaluation of lipid-based drug delivery systems (LbDDS), as already
mentioned in the “Advanced formulations” section of the paper,
in vitro tools combining dissolution-digestion-permeation evaluation
are scarce due to the complexity of properly capturing the continuously
changing intraluminal environment during lipid digestion. In addition
to a cell-based lipolysis-permeability system using Caco-2 cell line as
the permeation step [331], several cell-free systems, i.e. Permeapad
[332], PVDF filters treated with lecithin in n-dodecane solution [333]
and mucus-PVPA (phospholipid vesicle-based permeation assay
[334]), have been utilized in these combined model systems. Further
development of combined lipolysis-permeation models is however re-
quired to obtain better predictions of the in vivo performance of
LbDDS [188].
For lipophilic compounds, intestinal mucus is considered as an addi-
tional physical barrier that these compounds must cross before perme-
ating the intestinal epithelium layer. Several approaches were
introduced to investigate the impact ofmucus on intestinal drug perme-
ation including mucus-producing cell lines, collection of mucus from309animals or humans and the artificial preparation of mucus simulating
the in vivo mucus layer [335,336]. However, it is widely reported that
the composition of the mucus layer is changing according to the region
within the intestinal tract and between the luminalmucus layer and ad-
herent mucus layer which has an impact on its rheological properties
and barrier functions [337,338]. Further, several diseases are also
known to influence the mucus properties. Therefore, it becomes chal-
lenging to produce a model able to mimic physiological mucus, and
the differences between native and reconstitutedmucus can lead to var-
iations in the obtained drug permeability outcome. A standardized ap-
proach mimicking different types of mucus would thus allow to
improve ourmechanistic understanding of the impact of mucus charac-
teristics on intestinal drug transport.
In addition, it should be noted that the currently available perme-
ation models cannot mimic the true permeation rate observed in vivo,
due to a surface-to-volume ratio that does not correspond to in vivo con-
ditions: an aspect that is particularly important for the combined
dissolution-permeation models and is discussed in more details in the
next section.
These comments clearly indicate that themultitude of factors affect-
ing oral drug absorption will always complicate the use of predictive
in vitro experiments. Indeed, the dynamic aspect of theGIT environment
is not well captured bymost in vitro tools, usually considering the GIT as
a static environment with constant hydrodynamics, constant pH, high
GIT volumes and constant concentrations of surface-active substances
(e.g. bile salts, phospholipids, lipid digestion products) contributing to
colloidal structures. A single comprehensive tool mapping the full dy-
namic and complex nature of the humanbody, or even the intestinal ab-
sorption process will probably never exist. However, recent
advancements in the development of intestinal organoids are aiming
to bridge the gap between two-dimensional cell-based models and
in vivo models, thereby drastically improving physiological relevance
and in vivo similarity resulting in improved drug permeability evalua-
tion. Despite their complexity, intestinal organoids might be useful to
increase ourmechanistic understanding for various specific biopharma-
ceutical challenges and improving in vivo predictions [339]. Further-
more, in vitro experiments are typically designed using default
conditions representing averaged data from healthy volunteers for
predicting performance of drug products intended for a specific disease.
It is not surprising that intestinal permeability might be altered in spe-
cific diseases compared to healthy volunteers [31]. This could result in
a misprediction of drug product performance in the targeted patient
population andmay potentially be a cause for discontinuing the project
due to insufficient understanding of the problem. Consequently, it
would be relevant to focus on the development of disease-specific
in vitro (permeation) tools considering the GIT physiological modifica-
tions by the disease of interest which would finally result in better
performing drugs for the targeted disease.5.4. Combined dissolution-permeation models
The assessment of drug permeation together with dissolution test-
ing could provide valuable mechanistic knowledge that could be used
for better in vitro-in vivo correlations, especially when considering
food effects or advanced oral formulations with complex behavior in
the GIT.
In recent years, a range of dissolution-permeation assays has been
developed (Table 4) [14,340–346]. These typically consist of a donor
and receiver compartment separated by a membrane (i.e. cell mono-
layers [342,347], lipid (bi) layers [340,342,344–346] or dialysis mem-
branes [14,341]), mimicking the intestinal epithelium. In some of
these devices, intact dosage forms can be evaluated, whereas other de-
vices require downscaling of the dosage form (e.g. to powders) or pro-
cessing (e.g. pre-dispersion). Several dissolution/permeation setups
can be used in existing tools including the USP 2 [340] or the μDISS
Table 4
Dissolution/permeation setups.
Barrier A (cm2) V (mL) A/V (cm−1) Formulation Setup IVIVR Time (min)
IDAS2 [343] Caco-2 2.26 500 0.005 Intact Continuous Yes 120
MacroFLUX™ [340] lipid layer 3.8 1062 0.004 Intact Continuous Yes 240
MicroFLUX™ [346] lipid layer 1.54 20 0.08 Down-scaled/processed Continuous Yes 300
Vertical membrane flux [345] lipid layer 4.9 5 0.98 drug Continuous Yes 120
Hollow fiber module [341] dialysis membrane 100 50 2 Intact Continuous ND 300
AMI-system [14] dialysis membrane 4.91 0.7 7.38 Intact Discontinuous Yes 60–120
Permealoop® [344,350] Permeapad® 27.6 20 1.38 Down-scaled/processed Continuous ND 360
Digestion-permeation setup [342] lipid layer /Caco-2 27.28 20–60 0.45–1.35 Down-scaled/processed Continuous Yes 30–90
A: absorption surface, V: donor volume, A/V: absorption-surface-to-donor-volume-ratio, IVIVR in vitro in vivo ranking determined, ND not determined. Partly adopted from: ‘Dynamic dis-
solution-/permeation-testingMartin Brandl UNGAP/NordicPOP training school in vitro tools for evaluating the intraluminal and absorption behavior of advance drug formulationsOdense,
June 17th 2019’.
Z. Vinarov, B. Abrahamsson, P. Artursson et al. Advanced Drug Delivery Reviews 171 (2021) 289–331profiler™ [345,346], although, the routine implementation of such
methods in the pharmaceutical industry is limited.
Some of the reasons for the limited implementation of these novel
tools by the industry are poor validation, laborious preparation and
low throughput. For example, validation has often been performed for
one or a few compounds and formulation strategies and exploration of
food effect has only been done sporadically [340,348]. Resource optimi-
zation (materials and time) is also critical: cell- and tissue-based setups
are usually associated with lower throughput and feasibility issues,
compared to the more simple, membrane-based assays [14,341,346].
Hence, the adoption and routine use of dissolution-permeation tools
to support formulation development has yet to reach its full potential.
The permeation rates achieved in the dissolution-permeation
models are another important issue. In order to achieve a sufficiently
high mass transfer, setups should be optimized with regards to geome-
try and hydrodynamics to avoid aqueous boundary layers that limit
drug permeation, especially for lipophilic compounds. In addition, opti-
mal absorption-surface-to-donor-volume-ratios (A/V) should be ap-
plied: commercially available setups provide A/V values between
0.004 and 0.08 cm−1 whereas academically developed tools, reported
in the literature, reach values of 0.45–7.4 cm−1 (Table 4) which more
closely resembles the A/V in the human small intestine. Amidon et al.
have estimated that the A/V in the human small intestine ranges be-
tween 1 and 14 cm−1, depending on the degree of compression of the
cylinder-approximated intestinal geometry [349]. Evidently, sink condi-
tions, affected by the composition of acceptor media and the donor-
volume-to-acceptor-volume-ratio, are also crucial to maintain the flux
[329,330].
To facilitate implementation, existing approaches need to be opti-
mized with respect to their predictive value. This comprises the use of
in vitro data to predict in vivo PK, potentially through PBPK modeling.
For certain formulations, in vitro data needs to be generatedwith the in-
tact dosage form, as scaling down or processing can alter release and/or
dissolution profiles.
Moreover, it would be of interest to downscale and automate
dissolution-permeation assays. This has been successful in the past for
other biopharmaceutical tools (i.e. solubility testing, solid dispersion se-
lection and precipitation inhibition). High throughput screening capa-
bilities could be explored to satisfy the needs of biopharmaceutical
assessment although exploration of intact dosage forms might prove
to be challenging.
Finally, it should bementioned that to really simulate the in vivo pro-
cess of drug absorption, both the dissolution and permeation rates
achieved in the in vitro setup must mimic to an adequate extent (e.g.
at least in the order of magnitude) the corresponding processes in the
human GIT. A potential mismatch in the dissolution and permeation ki-
netics could lead to results that are not biorelevant and would require
careful analysis before any conclusions regarding the in vivo mecha-
nisms of drug absorption can be drawn based on the in vitro data.3105.5. Novel real-time analytics for supersaturating formulations
Supersaturating drug formulations are currently viewed as themost
promising to enhance the oral absorption of poorly soluble drugs. These
approaches include lipid-based systems, solid dispersions, as well as
other formulation techniques [351]. Such systems typically produce
complex colloidal dispersions inwater that are important to understand
along with the release kinetics of the drug [352]. While much progress
has been made to study overall formulation performance in vitro,
there is still limited understanding of such colloids formed in the GIT
fluids and how they interact with the drug, endogenous bile salts, and
phospholipids.
Different on-line, in-line and (to some extent) at-line analytical tools
can facilitate real-time analysis of supersaturating formulations. The
spectroscopic or other analytical techniques can be implemented in
classical compendial as well as non-compendial in vitro tests. It is possi-
ble to use for example immersion probes or flow-through cells for real-
time analysis of drug release and different methods were reviewed in
the literature [353,354]. While ultraviolet (UV) fiber optical probes are
these days widely used, other approaches such as UV imaging, Raman
or Fourier transform infrared (FTIR) spectroscopy or laser scanning
techniques have been used only occasionally for drug release/precipita-
tion analysis [353,354]. It is important to clarify what these analytical
methods can offer to biopharmaceutical testing as well as to learn
about these emerging new tools.
The different analytical probes have their particular advantages, but
also conceptual limitations. UV probes, for example, struggle with anal-
ysis of optically dense samples despite some improvement through the
preprocessing of raw data and multivariate data analysis [355]. For in-
line dispersive Raman spectroscopy, such data treatment allows mea-
surements in complex media, such as digested lipid-based systems,
but extensive calibration work is required when drug release is moni-
tored in solution parallel to the kinetics of optional precipitation [356].
While Raman spectroscopy is not particularly disturbed by the presence
of water, this is different in case of FTIR for which sophisticated sample
cells were used to study howdosage forms interactwith aqueousmedia
and how the drug is then released [357]. An even higher level of sophis-
tication is generatedwith synchrotron-based analysis of colloids formed
during dosage form disintegration and drug release [207]. This is cer-
tainly very attractive from a research perspective, but is hardly accessi-
ble for routine laboratory practice.
It would be desirable, especially for supersaturating formulations, to
measure the free drug fraction as this drives the absorptive flux across
the intestinal membrane. Ion-selective electrodes have been used for
this purpose and enabled measurement in turbid media [358]. How-
ever, an obvious disadvantage is the limitation to the ionized drug frac-
tion. In summary, the different real-time analytical methods provide to
some extent congruent, as well as complementary, information. All
techniques have their individual strengths and limitations for
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terest and evaluation of new sensor technologies is encouraged.
An emerging analytics procedure for in vitro testing is fluorescence
analysis. There are many techniques of fluorescence spectroscopy and
interestingly, they have hardly been explored to study supersaturating
formulations. Lynne Taylor's group reported on such an analytical fluo-
rescence approach to study supersaturated solutions from solid disper-
sions [359,360]. The researchers employed fluorescence lifetime and
steady-state fluorescence spectroscopy to study felodipine as it is
autofluorescent. The lifetime of free felodipine was shorter in simple
media compared to rich aggregates or in crystals. Subsequently, a re-
porter molecule (PRODAN) was further used to study its fluorescent
lifetime in presence of liquid-liquid phase separation of themodel com-
pounds clotrimazole and efavirenz [359].
Another research group used fluorescence quenching of celecoxib
and in particular the introduced (modified) Stern Volmer analysis ap-
peared to be highly interesting to study colloids emerging from solid
dispersions [361]. The accessibility of celecoxib by the quencher was
studied in physical mixtures as well as in solid dispersions and results
were highly interesting to achieve an improved understanding of
drug-polymer interactions of the dispersed amorphous systems [361].
Interesting is also a recent application of diffusion-ordered 1H NMR
to characterize the colloid species in biorelevant media and to study
surfactant-bile salts-drug interactions, which is promising to achieve a
better understanding of drug precipitation from supersaturating formu-
lations even in the absence of real-time measurement [362].
A further emerging technique is diffusingwave spectroscopy (DWS)
that was earlier used as a process analytical technology in
pharmaceutics [363]. More recent research applied DWS for the first
time to in vitro testing of solid dispersions and this technique bears
much promise from a biopharmaceutical perspective [364]. The ob-
tained microrheological information by DWS was found to be comple-
mentary to drug concentration kinetics studied by UV-fiber optical
analysis, which is a good example of how different analytical tools can
be combined [364].
There are certainly other analytical techniques that bear potential for
biopharmaceutical in vitro testing and more research is needed to de-
velop viable and complementary real-time analytics that can also be in-
dustrially implemented in drug release/precipitation testing.
5.6. Combining in vitro, in silico and in vivo data: ambitions for prediction of
oral product performance
Oral drug product design requires a thorough understanding of the
attributes which are critical for consistent performance in the GIT envi-
ronment. Traditionally, formulation scientists have relied on in vitro dis-
solution to guide product development with confirmation of product
performance coming from in vivo preclinical or clinical studies. More re-
cently, the limitations of compendial dissolutionmethods to adequately
predict in vivo performance has been widely recognized and a number
of alternative systems have been designed, as described in more details
in Section 5.2. Whilst undoubtedly useful for profiling formulation per-
formance and informing decisions on formulation design aspects, the
interplay between different variables can be difficult to deconvolute
cleanly as is necessary to establish a primary scientific relationship to
critical material and quality attributes.
The quest to improve predictive tools for oral absorptionwill need to
consider different paths towards delivering a step-change in our ability
to simulate the GIT and absorption processes. Significant, incremental
advances have been made with the adoption of new biorelevant
media [13,365], combined dissolution-permeation systems
[343,366–368] and models of the GIT, which integrate physiological
variables such asmotility, intralumenal pressure and dynamic digestion
[304,369–371]. Innovative engineering solutions continue to be devel-
oped to accommodate physiological factors within in vitro GIT simula-
tors [372] and biologically based solutions such as intestine on a chip311models [373] or intestinal organoids [374] offer orthogonal approaches
for assessing oral absorption potential.
However, can one realistically anticipate the development of a truly
holistic and readily accessible model absorption system which simu-
lates the totality of the physiological environment and integrates
physiologically-relevant hydrodynamics, transit and motility, dissolu-
tion, digestion and absorption? The challenges facing such a task are
amplifiedwhenwe begin to consider howwewould adequately accom-
modate true population patient variability incorporating physiological
and disease state factors. The use of computational approaches to pre-
dict oral absorption offers an alternative path forward to assess themyr-
iad of variables that need to be considered in tackling this challenge
[15,375–377]. However, the typical inputs for such software packages
capture the physicochemical properties of the drug and do not routinely
consider the impact of formulation or how excipients can modify the
biopharmaceutical performance of the active substance [378]. Combin-
ing dissolution results, ideally derived froma biorelevantmethodwhich
incorporates appropriate physiological variables, with a computational
approach is an extended solution to address this limitation [379–386]
but is limited in the sense that it delivers a bespoke solution for the com-
pound of interest. To extend this concept of combined in vitro and in
silico analysis to a broader compound set would require a multi-
componentfirst principles approach to be applied to all those properties
which determine bioperformance for both the drug and the formula-
tion. Such a functional biopharmaceutics profile “2.0” dataset would
need to move beyond static single point measurements for solubility
and intrinsic dissolution to a range of measurements which capture
the true range of clinical inter- and intra-subject variability. The same
concepts apply to dissolution measurements and in some cases (possi-
bly where active mechanisms predominate) to permeability values.
For ionizedmolecules, more nuanced datasets are required to fully eval-
uate the potential impact of precipitation processes on dissolution.
Studies of supersaturation and precipitation phenomena are widely re-
ported in the literature [214,387,388], and several reports describe suc-
cessful predictions of in vivo impact using in vitro data to guide in silico
models [389–393]. However, the ability to accurately predict solid
form, particle size and re-dissolution for precipitated weak bases after
gastric transfer remains beyond the current capabilities of the typical
biopharmaceutics toolkit. Another factor which requires consideration
is that much of our focus remains on physicochemically profiling the
drug, yet the conversion to drug product brings with it a number of in-
teractions and potential transformationswhich are very relevant from a
biopharmaceutics performance perspective. This is clearly exemplified
whenwe consider just two key properties for dissolution – drug particle
size and surface properties. Formulation processing can significantly
impact the final particle size in drug product through attrition or ag-
glomeration events. In some cases, it may be possible to utilize in vitro
dissolution to determine the effective particle size in drug product and
use this information as an improved input for absorption modeling
[394,395]. Surface properties of the drug are also altered by formulation
composition and processing. Lubricants have long been known to have
the potential to adversely affect the dissolution properties of a drug and
have come under the spotlight again in recent times with the trend to
move from batch to continuous processing sometimes resulting in ex-
tended lubrication levels due to the mixing technologies deployed
with some continuous processing platforms [396]. Empirically deter-
mining such effects may be necessary to better inform predictive
models of product performance. Excipients can also positively impact
the surface wettability of drug and thereby improve product
bioperformance [397]. Other opportunities exist to produce a functional
biopharmaceutics profile with a richer dataset than that of a traditional
general pharmaceutics profile and which critically inform the formula-
tion scientist of the properties which are essential for consistent
bioperformance. Placing a focus on the functional biopharmaceutics as-
pects of the drug to drug product development transition will enable
more sophisticated risk assessments to be performed than currently
Z. Vinarov, B. Abrahamsson, P. Artursson et al. Advanced Drug Delivery Reviews 171 (2021) 289–331achievable with a conventional approach. Returning to the question
posed on the future prospects for the development of a truly holistic
model of oral absorption, it is proposed that a more feasible near-term
target is to consider combining an end-to-end mindset and enhanced
technology toolkit to create a functional biopharmaceutics profile, as-
sembled from a better informed composite array of in vitro, in silico
and in vivo data, which reflect the pharmaceutical complexity of the
drug product and the physiological variability of the patient.
5.7. Biopharmaceutics modeling and simulation: limitations and strengths
PBPK modeling is an evolving toolbox with multiple applications in
drug research. In the following paragraphs, we report two emerging
points of view that can advance the field by (1) scrutinizing the meth-
odological approaches used or (2) focusing on the application in indus-
trial settings and translation to regulatory decision-making. The
ensemble of both views presents a holistic picture of the field that
spans from challenges in technical implementation to successes in
real-world drug development applications.
5.7.1. Limitations and threats in current PBPK modeling approaches
The limits and threats in PBPKmodeling aremainly attributed to two
factors: drug-by-drug parameter optimization (fitting) and publication
bias. Thesewill be considered in the next paragraphs. Then, a discussion
on other methodological and conceptual issues will be presented.
The parameter optimization of a PBPK model using clinical Cp-time
data is generally referred as “middle-out” approach that is different
from the “bottom-up” approach based on in vitro data and “top-down”
PK parameter calculation. There are two kinds of middle-out ap-
proaches, “global” and “local (drug-by-drug)”. According to the princi-
ples of mathematics, the number of coefficients identifiable from
observed data is limited by the degree of freedom and the model struc-
ture (parameter identifiability) [398,399]. In the case of the global
middle-out approach, parameter identifiability is usually well taken
care of (usually more than 4 drugs per parameter). Li et al. provide a
good example [400].
However, the local middle-out approach is controversial. The issues
of the local middle-out approach have been pointed out by FDA [162].
An oral PBPK model consists of a lot of parameters and equations,
whereas an oral Cp-time data of a drug offers only limited information
(the model is said to be “overparameterized”). Therefore, an i.v. PK
data arm is required to reliably calculate clearance, volume of distribu-
tion, and bioavailability of a drug (this is the invariable principle of
PK). However, the local middle-out approach is often performed with-
out i.v. data [401–405].
The local middle-out approach is usually used when the initial bot-
tom up prediction failed, because of inappropriate drug input data, de-
fault physiological parameters, incorrect model equations etc. In a
significant number of case studies of oral PBPK modeling reported in
the literature, parameter optimization has been used [401–409].
When the initial bottom-up prediction fails, a user of commercial soft-
ware may first suspect the drug input data. However, the physiological
parameters and/or model equations are not necessarily correct. Several
kinds of parameters can be altered in a drug-by-drug manner, until the
simulated Cp-time curve matches the clinical data. In the past, Peff and
the precipitation rate tended to be the target of parameter optimization
as these are not reliably predicted from in vitro data [401,406,407]. Re-
cently, scaling factors have been employed for parameter optimization
(c.f. scaling factors should be constant among drugs [400]). In some
cases, even physiological parameters were optimized in a drug-by-
drug manner [403]. In almost all cases, the failed prediction by default
setting is not shown, and the optimized data is published and being re-
ferred as “predicted”.
The use of parameter optimization or an empirical scaling factor
brings empirical statistic modeling into PBPKmodeling (semi-empirical
PBPK model). Therefore, we should follow the practice of empirical312statistic modeling. The parameter optimization function is provided in
commercial software and recommended in the literature. However, be-
fore performing parameter optimization, the identifiability of the pa-
rameters must be carefully examined. The degree of freedom must be
enough to avoid overfitting. The prediction skill should be evaluated
by cross-validation. The initial input parameters and simulation curve
before parameter optimization must be reported. A semi-empirical
PBPKmodel that is specifically optimized for a drug and a clinical situa-
tion should be used as interpolation within a limited parameter space
defined by the clinical data used for parameter optimization.Optimizing
one parameter hides the errors of the other parameters (the errors of
the other parameters are carried over to the error of the back-
calculated parameter).
With respect to the publication bias, the issue lies in the fact that
usually only the successful results from drug-by-drug studies are pub-
lished and used for regulatory submission. It is well known that a case
study is not regarded as reliable evidence in the medical sciences. Sys-
tematic studies are required to populate a reliable knowledge base
(like randomized controlled trials). Systematic validation studies have
been performed for the bottom-up prediction [17,410]. Similarly, sys-
tematic validation studies are required for the local middle-out ap-
proach using a standardized procedure.
A number of critical gaps in knowledge and conceptualmethodolog-
ical issues can be identified in PBPK modeling. For example, the “local”
middle-out approach has not been systematically validated. It is not
well knownwhen and underwhich condition, a parameter in a complex
PBPK model can be reliably identified from Cp-time data.
In addition, the interpretability of a model is often ignored. A “black
box” is often used. A “glass box” can be indecipherable when it is too
much complicated (“messy glass box”). In mathematical modeling,
PSA has been utilized to interpret black-boxmodels, such as deep learn-
ing. PSA could also be a useful tool for PBPKmodeling. However, relying
on PSA alone may inhibit a deeper understanding or an insight into the
system. PSA can be used as a support to diagnose the structural
identifiability. However, being a sensitive parameter is a necessary but
not sufficient condition to be structurally identifiable. Being an insensi-
tive parameter means that the clinical data offers no information about
the validity of the parameter. The knowledge about the rate-limiting
step is more important for formulation development. Once we know
the rate-limiting step of oral absorption of a drug, sensitivity analysis
is not required, because it is trivial that the parameters related to the
rate limiting step become a sensitive parameter. The sensitivity analysis
is necessary for a “black box” or a “messy glass box” model.
A PBPK model consists of a lot of parameters and equations (several
dozens to hundreds, or even thousands). Therefore, its descriptive
power is tremendous. It can perfectly reproduce every observed Cp-
time data by retrospective parameter optimization. However, a good
descriptive power does notmean a good predictive power. Even though
it is counter intuitive, as the number of model parameters increases, the
predictability often decreases because the errors of parameters and
model equations exponentially accumulate as the model becomes
more complex. Therefore, practically, a simpler model often shows a
better predictive skill [410]. In science, this paradox has been solved
by applying the Occam's razor principle. This principle has been applied
to PK, population PK, and PK/PD area [411]. Therefore, the same princi-
ple should also be applied to oral PBPK modeling. A simple model
should be used unless a more complex model shows statistically signif-
icant improvement by systematic studies for prospective prediction.
A local middle-out approach is usually used to simulate RBA such as
the food effect and the gastric pH effect. In these cases, one or two com-
partment models can be used to simply describe the post absorptive
processes.
It is critically important to improve the literacy ofmodeling and sim-
ulation. A publication guideline is required for PBPK modeling. The sci-
entific validity of a research article is the author's responsibility, even
when using commercial software. All model equations and
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perform peer-review by the referees and the readers who do not have
access to commercial software. The model must be a “glass box”.
Current commercial software products show markedly different
prediction characteristics, even when using the same input drug data
[410]. When two commercial software products show different results,
which one should be used for regulatory submission? A potential solu-
tion is to use harmonized model equations and physiological data sets.
The model equations and physiological parameters should be open
and freely accessible to everyone to enable public check. At the same
time, commercial software venders can provide a useful graphic user in-
terface and various utility tools. This businessmodel has been successful
in chemistry and the fields, maintaining the scientific integrity while
promoting the use of the model for the benefit of society [412–414]. A
systematic validation study of the local middle-out approach should
be performed before it is used for regulatory submission.
5.7.2. Progress in PBPK modeling for regulatory questions
The concept of the PBPK model was first published in 1937 by
Torsten Teorell [415]. However, the approach remained unexplored
for 40 years until, towards the end of the 1970s, a few academic papers
appeared. In the 1990s scientists working on environmental chemicals
began to apply and publish on PBPK and eventually in the early 2000s
use within the pharmaceutical industry started [416]. Shortly after
2010, use of PBPK picked up and a rapid risewas seen in pharmaceutical
related publications until 2017, when both the FDA [417] and the
EuropeanMedicines Agency (EMA) [418] released draft guidance docu-
ments. Initially, regulatory use of PBPK at the FDA was limited to the
evaluation of metabolism-related drug–drug interaction potential, spe-
cifically to substrates of cytochrome P450 (CYP) 3A and 2D6 enzymes
[419]. This was supported by confidence in this area of application
established based on systematic analyses for multiple compounds. For
example submissions from 9 sponsors for 15 different substrate PBPK
models were reanalyzed at the FDA to support the reliability of applica-
tion for metabolic related DDI [420] and subsequent analyses have pro-
vided further support [421]. Confidence in other areas of application
was limited due to the lack of sufficient experience of the regulators in
these areas due to a more limited number of submissions received
[419]. In contrast, workers in industry had higher confidence in broader
applications, including those related to drug absorption where PBPK
was predominantly used to answer questions related to company inter-
nal decision taking [422].
Expansion of the areas of application of PBPK for regulatory ques-
tions has continued steadily, building upon the collection of further ex-
amples and the sharing of combined analyses for different types of
application. Thus, use for prediction of changed PK due to CYP3A en-
zyme induction is supported by an analysis of 11 substrate PBPK
models, developed by six sponsors [423] whilemultiple published anal-
yses performed in the past 10 years have supported the application of
PBPK for scaling of PK to children [424–427]. While oral absorption
modelingwas initially of lesser impact for regulatory questions, this sit-
uation is changing. Recent publications have presented exampleswhere
consistent methods have been applied across a range of compounds to
simulate food effects [409,428,429] and gastric pH-dependent DDI
[430,431] and the potential for wider application is well recognized
[432,433].
Regarding the steps needed to build confidence in PBPK modeling
for specific applications, it is notable that the PBPK models used to
waive clinical studies for metabolic DDI are rarely purely bottom up
models which rely solely on in vitro data. For example, prior to use of
a PBPK model to waive a clinical study with a moderate or weak
CYP3A4 inhibitor, it is recognized that the model must first be verified
(and potentially optimized) using data obtained in a clinical study
with a strong inhibitor. This type ofmiddle-out fitting to clinical data re-
quires that best practices are developed and aligned within the PBPK
modeling community. Best practices cover the need for PBPK model313input data of sufficient quality, appropriate level of verification of
models with clinical data, the degree of parameter optimization which
is acceptable and confirmation of the plausibility of the final model
used for predictions [434]. This process of definition and alignment of
best practices is key to the advancement of PBPK ensuring that decisions
taken based on modeling are made with sufficient confidence. There-
fore, open discussion at scientific conferences and workshops has
been essential [435,436] and continues to be key as the application to
biopharmaceutics attracts more interest [433,437]. A recent publication
of and requests for comments on a draft guidance covering “The Use of
Physiologically Based Pharmacokinetic Analyses-Biopharmaceutics Ap-
plications for Oral Drug Product Development, Manufacturing Changes,
and Controls” [438] is a further step towards wider application of PBPK
for regulatory questions.
6. Food-drug interactions
6.1. Introduction and scope
The administration of drugs atmealtime is a decades-old problem in
drug development, due to the frequent and sometimes extreme effects
of food (positive or negative) on drug PK. As the food-drug interactions
can occur onmany levels and stages of drug action in the body, they still
remain very difficult to predict both in vitro and in silico. Hence, a num-
ber of aspects of the current knowledge on food-drug interactions are
critically examined and questioned in the following paragraphs. The un-
charted area of gut microbiota interactions with pharmaceutical com-
pounds and the possible significant impact on drug PK are also
explored in detail, providing valuable insight on an emerging topic in
the domain of oral drug absorption. The impact of dietaryfiber-colon in-
teractions on the general well-being and drug absorption is also
discussed. Finally, the opinion of two COST actions focused on food
and nutritional supplement-related topics that can interact with intesti-
nal drug absorption provides awider, interdisciplinary viewon the topic
and demonstrates its significance to the general audience. The main
gaps and the proposed way forward in the area of food-drug interac-
tions are summarized in Fig. 12.
6.2. Administration of drugs with food as a strategy to increase oral
bioavailability
The observation of strongly positive food effects in the case of vari-
ous oral anticancer drugs was the starting point of an intense debate
about the intake recommendations for these drugs [439–441]. For
drugs such as abiraterone acetate or sonidegib, the oral bioavailability
after a high-fat meal can be up to 10 times higher than in the fasted
state [442,443]. However, since this food effect may strongly depend
on the type of food consumed and is therefore difficult to control in
real life, many oral anticancer drugs with positive food effects are rec-
ommended to be taken on an empty stomach [444]. In this way, the
risk of undesired overdosing shall be minimized. Various scientists
argue, however, that for drugs such as lapatinib the co-administration
together with food can reduce the pill burden and thus, drug therapy
costs [445]. In addition, an enhanced drug absorption may also reduce
the risk of local side effects in the GIT. The question is therefore: how
can we use the occurrence of a positive food effect for the benefit of
the patient?
The occurrence of positive food effects can be triggered by various
physiological effects that are caused by the intake of food and/or caloric
liquids [3]. These include increased concentration of bile salts in the
small intestine, delay of gastric transit or the presence of dietary lipids.
For many drug products, however, the key mechanism driving the
food effect is often unknown. Thus, the food effect is hardly controllable
since concrete, actionable recommendations cannot be derived for the
patient. Against the background of very different dietary habits and
disease-related changes in the GIT, the administration of drugs with a
Fig. 10. Physiological factors associated with the intake of fibre.
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real life as strong intra- and inter-individual fluctuations in drug Cp may
occur. In particular, the recommendation to take a drug with a well-
defined meal that shall lead to a certain food effect, should remain an
exception. Such a procedure is hardly practicable in the long run (e.g.
due to polypharmacy) and also has negative effects on the patient's
compliance.Fig. 11. Effect of Lactulose and codeine on dispersion of [111In] labelled Amberlite resin in t
Reproduced from Hebden et al. with permission [489].
314It is therefore necessary that we closely examine the mechanisms
leading to the occurrence of food effects. Thanks to various initiatives
such as the EU project OrBiTo (Oral Biopharmaceutics Tools) or the IQ
consortium, a whole range of powerful in vitro and in silico models are
already available to study and predict food effects [27,409,446].
Thereby, the selection and application of a suitable biorelevant in vitro
or PBPKmodel should be based on the properties of the drug substancehe colon and systemic concentrations of quinine delivered by a colon targeted device.
Fig. 12. Food-drug interactions summary.
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Unfortunately, a one-size-fits-all approach is currently not available. To
further improve and optimize these tools, a deeper understanding of the
various processes occurring after oral drug administration in the human
GIT is needed. Amongst others, this also includes the transit and release
behavior of orally administered drug products in both fasted and fed
state. In this respect, combined studies in which classical PK analysis is
combined with a specific imaging or diagnostic method (e.g. MRI, aspi-
ration, telemetric capsules) can provide further insights into the mech-
anisms leading to the occurrence of food effects [447]. However, in
many cases the link between the in vitro release behavior of an oral
drug product and the actual in vivo release is still unknown. To improve
the physiological relevance of the in vitro data, the different methods
used to assess drug release and absorption need further optimization
and validation based on in vivo data. In addition, the PBPK models
must be optimized as well and should be increasingly used to generate
and verify hypotheses.
If the mechanism of a food effect can be identified with the help of
these tools, an attempt should bemade tominimize the effect by chang-
ing the formulation. In the sense of an effective use of the administered
dose, however, the formulation strategy should aim at maximizing the
bioavailability in the fasted state and not atminimizing the bioavailabil-
ity in the fed state. This can be done, for example, by advanced or ‘en-
abling’ formulations. In the past, it has already been successfully
shown that a food effect can be minimized by certain formulation con-
cepts [448].
In conclusion, the recommendation to take the drug together with a
meal represents a barely controllable risk, especially in the case of drugs
with a narrow therapeutic window. Instead, a better understanding of
the mechanisms leading to food effects on oral drug bioavailability is
needed to minimize food effects in the drug development process. For
this purpose, we need a deeper comprehension of human GIT physiol-
ogy along with improved in vitro and in silico tools able to describe
and predict food effects.
6.3. Application of physiologically based models to predict food effects: cur-
rent status, strengths and limitations, next steps
PBPK modeling is often applied for the prediction of food effects
using the advanced absorption models in commercial software315platforms such as GastroPlus™ and Simcyp®. However, despite multi-
ple published examples for individual drugs [449–451], the health au-
thorities still lack confidence in predictions and neither the recently
updated FDA guidance on the conduct of food effect studies [452] nor
guidance from other agencies havementioned the utility ofmechanistic
studies of food effect using in vitro and in silicomodels. Thismismatch in
confidence assigned to PBPK applied for food effects currently hampers
regulatory impact.
Current PBPKmodel platforms cover only a subset of the full range of
mechanismswhich can lead to food effect and so predictionsmay be re-
liable when the predominant food effect mechanisms are captured but
will be poor if key mechanisms are missing. To assess confidence in
the food-effect prediction for a particular drug and formulation it is im-
portant to identify the major mechanisms a priori based on, for exam-
ple, molecular properties and in vitro measurements and also to
establish a consensus on the mechanisms where PBPK predictions are
reliable.
The success of simulation approaches is also critically dependent on
the quality of input data, which should be generated using biopredictive
methods. Definition of best practices for assay selection and measure-
ment methods for generation of input to models for prediction of food
effect is needed. Furthermore, appropriate translation of parameters
from in vitro to in vivo needs to be applied, which may involve model-
based analysis of data generated with biopredictive methods [16]. The
mismatch in confidence levels between industry and regulators is also,
in part, due to a lack of agreed best practices for model development.
Therefore, a broad effort to define a consistent modeling strategy for
food effect prediction and to agree on the definition of adequate verifi-
cation data is required.
To this end, a recent cross-company effort proposed a decision tree
for model verification and optimization and supported this strategy
with five case studies [409]. The strategy did not recommend complete
elimination of clinical food effect studies via PBPK modeling but rather
proposed a streamlined approach where verified food effect models
could be leveraged to project effects into different dosing situations
e.g. new formulations or different dose levels. Expanding on this work,
food effects for 30 diverse drugs were analyzed in a larger
cross-industry consortium study [428]. This study performed a well-
controlled assessment of PBPK food effect modeling, minimizing con-
founding factors, such as inconsistent data generation, subjective
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compound types and mechanisms, which could be modelled with con-
fidence, were found to be those related to changes in GIT motility, pH
and luminal fluids (e.g. changes in bile salts).
A recent UNGAP review on the “Food-Drug Interface”, summarized
the many different mechanisms that can lead to PK food-drug interac-
tions considering also formulation performance and how specific food
types can lead to food-drug interactions [3]. PBPK models already cap-
ture some, but not all, of these mechanisms. However, work is ongoing
to verify predictions for the mechanisms which are captured and high-
light areas where current in silico and in vitro approaches are inade-
quate. Verification needs to continue, and the gaps should be
prioritized accounting for the molecule types common in current phar-
maceutical development pipelines. Having done this, research efforts
should be proposed to fill the gaps and extend the range of confidence
in predictions.
6.4. Opinions from other COST actions
6.4.1. Food-drug interactions: a perspective from the INFOGEST network
INFOGEST is an international network on food digestion, gathering
scientists from more than 150 institutions in 45 countries. It has pub-
lished consensus protocols for performing in vitro digestion in static
[453] and semi-dynamic conditions [454] and has recently underlined
the advantages and limits of static and dynamic in vitro digestion
models [455,456].
The potential for food to affect drug absorption has been known for a
long time [457] and multiple examples and aspects have already been
covered in the previous section. Although we now have increasing
knowledge of how food can affect drug metabolism and absorption,
the opposite effect i.e. how a drug will affect food digestion has scarcely
been studied. This is still a significant knowledge gap that needs to be
filled. For instance, it is unclear how salivary stimulants or sialagogues
affect bolus formation in the mouth and how subsequent dilution in
the GIT affects the kinetics of nutrient release. Also, in the stomach, pro-
ton pump inhibitors limit gastric acid secretions and increase the gastric
pH. An increase in gastric pH would decrease proteolysis since the opti-
mal pHof pepsin is around 2 and is inactive at pH 3 andwould therefore
increase the relative activity of α-amylase that has an optimum above
pH 5. However, to the best of our knowledge, this has never been stud-
ied in detail. Similarly, laxative agents that evacuate soft-formed stools
without griping and loss of waterwill affect transit time and thus the ki-
netics of nutrient absorption.
There is therefore a strong need for new research to clarify the effect
of food on drug absorption, but also the effect of drugs on food digestion
and absorption. In vitro models of digestion are crucial tools to unravel
these interactions. Among them, static in vitro digestion models can be
considered as screening tools to quickly see, in simplified conditions, if
a drug will interact with a food or vice-versa. Dynamic models are
more complex and more physiologically relevant since they take into
account factors such as food transit, the evolution of pH and the secre-
tion of enzymes and bile in real time. They are promising tools for diving
more profoundly into the mechanisms of interaction between drugs
and food. By joining their efforts, UNGAP and INFOGEST will have all
the skills needed to fill remaining gaps in knowledge about food-drug
interactions and their long-term impact on health.
6.4.2. Absorption of carotenoids: a perspective from the Eurocaroten
consortium
6.4.2.1. Carotenoids: versatile bioactive compounds of interest for the food,
pharmaceutical and (nutri)cosmetic industries. Carotenoids are dietary
components of great importance as natural colorants and, some of
them, as precursors of vitamin A. More recently, evidence has accumu-
lated that carotenoids can be involved in health-promoting actions con-
tributing to a reduced risk of developing cancers, cardiovascular disease,316skin-, bone- or eye conditions, and even metabolic disorders [458,459].
Hence there is an increased interest in the context of the development
of functional foods and related products, such as supplements used as
nutraceuticals. Being one of the main contributors of skin colour
(along with melanin), carotenoid supplements are also used as
nutricosmetics. Furthermore, some carotenoids (canthaxanthin,
β-carotene) have been used to treat skin disorders such as erythropoi-
etic protoporphyria [459–461]. Thus, carotenoids are very versatile
compounds that, beyond the food industry, are of interest for the phar-
maceutical and (nutri)cosmetic industry.
6.4.2.2. Assessment of the main phenomena related to carotenoid absorp-
tion. Beyond matrix differences, the bioavailability of carotenoids de-
pends on factors including interindividual dietary, genetic and
physiological differences. The use of in vitro digestion models with con-
trolled conditions has become very popular to assess the potential for
drug absoprtion. Nowadays, the methodologies used are often based
on the consensus static protocol of the INFOGEST COST Action [453].
This approach is helpful to assess bioaccessibility, which usually refers
to the fraction of carotenoid ingested that is potentially absorbable.
The term “bioaccesibility” is not commonly used in intestinal drug ab-
sorption research; however, it is also being used as an output parameter
of TIM experiments (see Section 5.2). Normally, the carotenoid fraction
incorporated into micelles is considered as bioaccessible [462].
Bioaccesibility of carotenoids has been shown to be well-correlated to
their bioavailability [463–465]. In a typical bioavailability study, a
carotenoid-rich matrix is provided to human volunteers and changes
in the carotenoid plasma levels are evaluated, either after a single
meal [466,467] or over several days. [468,469].
Key phenomena involved in the absorption of carotenoids have been
explored in detail in various recent studies. For instance, in order to gain
insight into differences in uptake among several dietary carotenoids,
Mapelli et al. [470] assessed their incorporation into artificial mixedmi-
celles, as well as their uptake and efflux by Caco-2 cells. The possible in-
volvement of proteins, such as cluster determinant 36 (CD36),
scavenger receptor class B type I (SR-BI) andNPC1 like intracellular cho-
lesterol transporter 1 (NPC1L1) in the absorption was assessed in Caco-
2 cells. The results were compared to those obtained in GripTite cells
(genetically engineered Human Embryonic Kidney (HEK 293-T) cells)
[470]. On the other hand, differences in site-dependent intestinal ab-
sorption of dietary carotenoids (phytoene, phytofluene, lycopene and
β-carotene) have been studied in wild-type C57BL/6 Rj mice. It was
demonstrated (1) that phytofluene presented a significantly higher bio-
availability compared to lycopene and β-carotene, (2) that β-Carotene
was mostly converted to vitamin A in the proximal and median intes-
tine, and that the accumulation of phytoene and phytofluene tended
to be more important in the distal intestine [471].
6.4.2.3. Research needs. Being lipophilic dietary components of great in-
terest forwell-beingpromotion, the demandof carotenoid supplements
has experienced an important increase in recent years. Since they can
adopt pharmaceutical formats, interdisciplinary research by scientists
with a background in food science and technology, nutrition and phar-
maceutical sciences could contribute to carotenoid-rich supplements
with optimized bioavailability. For instance, reduced particle size or for-
mulation with oil could result in a markedly higher bioavailability as
compared to that of food sources [462]. However, further studies on
the absorption of carotenoids formulated as supplements are needed,
including studies on the fate of compounds not absorbed in the small in-
testine, absorption in various populations (age, ethnic groups, individ-
ual with particular diseases/digestive conditions), the influence of
habits (alcohol, smoking, sports), the role of the mucus layer which
covers the intestinal lining, or the interaction with other compounds
(formulation ingredients, dietary compounds, drugs) [465,472]. Within
this context, adoption of advanced in vivo, ex vivo, in vitro and in silico
tools and technologies, as described in previous sections, by the food
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motion of health through the consumption of carotenoid-rich products.
6.5. Exploring the impact of colon-fibre interactions on health and drug ab-
sorption: historical perspective and recent results
“Dis-moi ce que tu manges, je te dirai ce que tu es”
[Anthelme Brillant Savarin]
Humans in pre-civilisation times moved from living in woodland
and patchy forest, encountering harder, mechanically-challenging nu-
trition including legumes, grain and large nuts which could be stored
when food availability became scarce [473]. The modal life span of
these paleolithic humans was 68–78 years and death occurred by star-
vation, traumatic injury or infection. Researching extant tribes, Gurvan
& Kaplan identified three established behaviours for sourcing food:
hunter-gatherers, forager-horticulturalists and third group including
acculturated foragers [474]. In the paleolithic era (the old Stone age), se-
lective genetic pressure assisted the survival and reproductive success
of Homo sapiens, spilling the species out of Africa into the modern
world over an era that spanned from 2.5 million to 11,000 years ago
[475]. The agricultural revolution started in the Middle East in the Neo-
lithic era (10000–4500 B.C.) and spread the population globally.
Carrera-Bastos and colleagues point out that the period from the end
of the Paeolithic era spans only 366 generations, that from the Industrial
Revolution seven generations and modern times encompassed within
four generations! [476] This means that to understand the ability of
the gut to process food, we should always look back in time to our ear-
lier diets because the human genome has not evolved fast enough to
cope with starkly changed meals of today.
The function of the colon in nutrition is well versed. Although
human beings can survive without a colon, surgical intervention to di-
vert a section of small bowel or stoma surgery and changes to eating
pattern are needed to survive. Solubilisation and extraction of nutrients
by digestion requires physical processing of the food matrix and enzy-
matic action. Ease of access of nutrients to the systemic circulation is
therefore conferred by homogenization to present a high surface area
as in processed foods, snacks and treats. Although this generally in-
creases the energy density of the matrix, processing is increasingly
used to generate putative health benefits centred around the consump-
tion of extra fibre.
In a varied healthy diet, there will be some components, principally
carbohydrates (soluble fibre) which will resist degradation in the small
intestine and be presented to the colon. This will be in addition to insol-
uble fibre components, collagenous matter, cells and mucus shed by
surfaces. The papers by Cummings and others underpin our knowledge
of the interaction of fibrewith the GIT [477]. The gastroenterologists fed
volunteers wheat fibre and examined faecal output. As the fibre intake
was increased there was an elevation in faecal fat, calcium and nitrogen
output and more mixing occurred in the gut resulting in a spread of co-
ingested radio-opaque markers. The faecal weight increased three fold,
primarily by water retention in the fibre and the excretion of volatile
free fatty acids increased. The identity of the short chain fatty acids – ac-
etate, butyrate and propionate generated by colonic anaerobic bacteria
and the redox potential generated after feeding complex carbohydrate
diets can be sufficient to produce hydrogen and methane [478]. This is
detectable in breath.
The principal sugars unabsorbed in the small intestine were noted as
lactose, raffinose and stachyose [479]. These sugars and the sugar alco-
hols, sorbitol and xylitol are broken down by the bacteria. The total fer-
mentable carbohydrate as sugars, starches and other compounds
presented to the colon was estimated to be 5 g per day. Bacterial diges-
tion of fruit fibre releases polyphenols, which in vitro screens suggested
to have putative anti-oxidant, anti-inflammatory and even anti-cancer317properties [480]; however, the agents such as anthocyanins are released
as glycosides and the individual bioavailabilitymay vary according to the
hostmicrobiota [481]. It has been speculated that the polyphenolsmight
influence the digestion of the fibres as both anti-bacterial and pro-biotic
effects have been recorded [482]. Pre-biotics, fibre-basedmatrices which
increase the growth or control the diversity of microbiota have received
much interest andwere recently reviewed [483]. The early origin of their
health benefit was probably the research showing oligosaccharides in
breastmilk are important for the establishment of the infantmicrobiome.
They generally consist of inulin or galactan structures and the benefits
are vague since the compounds areweak pharmacophores. The principal
finding after longer term exposures is an increase in bifidobacter sp. and
perhaps a reduction in harmful bacteria although the latter has not been
accepted by the European Commission [484].
The physiological factors associated with intake of fibre, assimilated
from a number of authors, are presented in Fig. 10.
Fibre contributes to the viscosity of GIT contents, whichmay impact
on availability of drugs or nutrient. The overall effects are complex be-
cause stomach and colon motility may be affected differentially.
Lactulose administration (20 mL t.d.s.) has been used to produce a
model of diarrhoea [485,486] to study GIT transit of dosage forms, the
absorption of drugs and strategies to control diarrhoea. Psyllium is ob-
tained from plantago seed husk and forms a gel that resists digestion
and increases stool water. It delays gastric emptying through viscosity
effects and reduces the accelerating effects of lactulose by decreasing
fermentation rates in the caecum and ascending colon [487]. The
colon timed release system “Pulsincap’ was used to isolate the colonic
drug delivery component [488]. Using the Pulsincap loaded with
[111In] labelled Amberlite resin, [51Cr]- EDTA and quinine
dihydrochloride (10 mg), Hebden and colleagues produced models of
constipation and diarrhea by treatment for 5 days extending into the
study day with codeine (30 mg qds) or lactulose 20 mL tds [489]. The
control arm and all treatment arms had controlled fibre intake prior to
the study day. Dispersion, drug absorption and urinary recovery were
measured in sixteen subjects in a 3-way randomized crossover design
using Pulsincaps with 5, 6 or 8 h delay plugs. Lactulose pretreatment re-
sulted in an increase in colon water leading to greater dispersion of the
particles and a faster rise to Cmax for quinine as shown in Fig. 11whereas
codeine treatment produced lowest dispersion scores and a decrease in
urinary [51Cr]- EDTA excretion.
In summary, the food interacting with the colon has passed by the
main sites of absorption, but fermentation of complex carbohydrates
control glucose utilization, release micronutrients that can be absorbed
and alter the microbial population. The intake of poorly fermentable fi-
bres supplanting soluble, fermentable fibres stimulates peristalsis by re-
moving the disruptive effects of gas on the efficacy of weak peristaltic
waves in propelling colonic contents towards the descending colon.
The individual differences produced in a sustained dietary habit change
the response to fibre and diverse exposure broadens the genera of mi-
crobes that will occupy the microbiome. The physiological roles of
fibre in the gut are diverse and probably affect immunity and many as-
pects of health status [490].
To revisit the famous Brillant-Savarin aphorism we might consider
this conversation between a scientist now and a person from the Old
Stone Age:
“Tell me what you eat and I will help you understand how your colon
works!”6.6. The role of the intestinal microbiome
The fate and activity of drugs are frequently dictated not only by the
host per se but also by themicroorganisms present in the GIT.While the
ever-increasing scientific breakthroughs have highlighted the influence
of the gut microbiota on host health, mechanistic insights on the role of
Z. Vinarov, B. Abrahamsson, P. Artursson et al. Advanced Drug Delivery Reviews 171 (2021) 289–331the microbiota on the absorption of orally administered drugs remain
relatively understudied. Elucidating the possible mechanisms by
which the gut microbiota might influence or contribute to altered
drug absorption in vivo is thus warranted.
It is being increasingly recognized that the gut microbiota is not
static, but subject to dynamic transformations as a consequence of phar-
macological interventions (e.g. antibiotic therapy), pathology
(gastroenteric and systemic infection), nutritional status, circadian
rhythm and environmental influences [491,492]. In addition, the gut
microbiome is now known to play a critical role in health homeostasis,
and directly influences host metabolic processes and immunological
functionality. Inter-individual temporal microbiota diversity, or
dysbiosis, is thus of potential clinical significance, leading to changes
that may directly impact drug metabolism such as bacterial enzymatic
activity (e.g. fecalase) but also indirect changes in host metabolic activ-
ity (e.g. change expression of host genes implicated in drug metabolism
and/or transport). However, it remains unclear how these changes in
gut microbiota will impact drug absorption and bioavailability after
oral administration.
While gut microbiota can both directly metabolise drugs and in-
directly influence host-metabolising capacity of drugs, as recently
reviewed [493,494], the molecular understanding of microbiota-
mediated effects on drug bioavailability is still rudimentary. A lim-
ited number of reports in the literature have explored the impact of
microbiota mediated changes on oral bioavailability in vivo. Microbi-
ota mediated changes, via administration of the probiotic Escherichia
coli strain 1917 (EcN) for seven days to rats, significantly increased
amiodarone bioavailability by 43% in comparison to saline-treated
control rats [495]. The effect was not evident when using a reference
non-probiotic E. coli strain (non-commensal), which suggests that
the microbiota-mediated changes in amiodarone bioavailability
may be strain-specific. In the case of gliclazide, the oral bioavailabil-
ity was significantly reduced 3-fold in rats following three days ad-
ministration of a probiotic cocktail [496]. Interestingly, probiotic
treatment did not influence systemic clearance of gliclazide after i.
v. administration, which indicated that the microbially-mediated al-
terations influence the intestinal absorption of this drug. While nei-
ther of these studies demonstrated a confirmatory mechanism for
altered absorption of these two drugs, it was speculated that altered
intestinal transporter/enzyme expression may be involved. In the
case of paracetamol, probiotic treatment (Lactobacillus reuteri) sig-
nificantly reduced oral bioavailability by ~30% in mice, whereas
drug levels after i.v. administration remained unaffected [497]. In
this study, a mechanistic basis for the reduced oral absorption was
provided: L. reuteuri was shown to be capable of directly metaboliz-
ing paracetamol; this probiotic was also shown to alter arylsulfate
transferase and β-glucuronidase activity, which are bacterial en-
zymes that are specifically involved in paracetamol metabolism.
It is also increasingly being recognized that the gut microbiota plays a
role in intestinal homeostasis, such as metabolism, and that the expres-
sion of hepatic genes implicated in drug metabolism displays sensitivity
to the alteration in the microbiome effects. For example, the production
of two short chain fatty acids, butyrate and propionate, by intestinal bac-
teria has been shown to alter liver gene expression, leading to changes in
CYP450 activity inmice [498]. In addition, the intestinalmicrobiomeplays
a role in homeostasis of bile acid composition, which can influence bile
acid signaling in the intestine, but also affect the solubilization capacity
of bile micelles for poorly water soluble drug [499].
Another potential factor influencing inter-individual variation
in microbiota-drug associations relates to the impact of drug in-
duced changes of the gut microbiome. Accordingly, coadministra-
tion of drugs affecting the metabolic activities of gut microbes
may lead to DDI. The interaction between broad-spectrum antibi-
otics and oral contraceptives represent a classical clinically-
relevant example of the potential impact of depletion of gut mediated
deconjugation on reducing overall drug levels of estrogens in patients.318However the impact of antibiotic-induced suppression of gut
microbiome may also impact other drugs, such as the increased bio-
availability of aspirin observed in rats [497]. The potential effects are
not limited to antibiotic-induced microbiota depletion, given that any
drug that directly alters the GIT environment (e.g. pH and transit
time), mucosa integrity, host and bacterial metabolic activity may con-
sequently affect microbiome composition with the potential to lead to
DDI [494]. This is particularly relevant given recent reports of the exten-
sive impact of non-antibiotic drugs on the gut microbiota [491]. The
study of Maier et al. screened >1000 marketed drugs against 40 repre-
sentative gut bacterial strains, and found that 24% of the drugs with
human targets (i.e. non-antibiotics), inhibited the growth of at least
one bacterial strain with 40 drugs inhibiting the growth of up to 10 dif-
ferent bacteria [491]. While the increasing in vitro and preclinical stud-
ies re-affirms the importance of accounting for drug-induced changes in
the gut microbiota as a potential confounder in drug PK there is pres-
ently a paucity of studies in humans to support the translation of
these findings to the clinical setting. A clinically relevant example is
that of levodopa treatment of patients with Parkinsonism, where the
presence of the bacterium H. pylori decreases the absorption of levo-
dopa. Hence, antibiotic mediated eradication of H. pylori was shown to
significantly improve clinical symptoms of patients with Parkinson's dis-
ease [500]. However, these findings merely explained the potential
source in inter-individual variability in Parkinson's disease patients
which have a high abundance of H. pylori. More recently, the ability of
enterococci bacteria harboring tyrosine decarboxylases (TDC) to reduce
absorption of levodopa from the small intestine has been reported.
Studies in Parkinson's disease patients revealed that the relative abun-
dance of bacterial-derived TDC enzymes in faecal samples was posi-
tively correlated with a higher daily dose of levodopa [501]. This
study may therefore potentially identify a ‘Pharmacomicrobiomics’ ap-
proach for individualising levodopa dosing in Parkinson's disease pa-
tients where gut bacteria, or their encoded TDC gene, may be used as
a predictive biomarker to adjust levodopa dosage levels in Parkinson's
disease patients. There is clearly a need for more clinical studies to ex-
plore further examples of drug-microbiota interactions, as a potential
cause of significant inter-patient variability.
The role of the gut microbiota on influencing oral absorption of
polyphenol-based nutraceuticals has also been extensively re-
ported. The bioavailability of polyphenols are known to display
high inter-individual variation depending on factors such as age,
gender, genotype, and more recently gut microbiome composition
[502–507]. For example, rutin (quercetin-3-O-rutinoside), is a die-
tary flavonoid that is converted to isoquercitrin and further to
quercetin by the colonic microflora, and therefore overall bioavail-
ability of quercetin is dependent on their cleavage by intestinal
microbiota [508]. Variability among individuals in rhamnosidase-
producing bacterial strains may therefore lead to inter-individual
variability in the bioavailability of quercetin [509]. However, as
for other polyphenols, clinical data supporting the link between al-
tered gut microbiota and reduced bioavailability of such
polyphenol-based nutraceuticals is still lacking.
In summary, there is an increasing understanding of the dynamic
host-microbiome interplay, shedding new insights into disease progres-
sion and affording novel opportunities to develop microbiome-based
therapeutics. Within this emerging field, there is a need to address gaps
in our knowledge on how these dynamic host-microbiome interactions
influence drug absorption. Further studies are therefore required to pro-
videmoremechanistic insights on how changes in themicrobiota evolve,
as a result of diet, age, health status and drug treatment, that can lead to
clinically relevant changes in drug absorption [498]. On a broader level,
the functionally modifiable nature of the microbiome offers the unparal-
leled opportunity to apply microbiota-targeted interventions and
pharmacomicrobiomics tools to address related variability in drug ab-
sorption. Further studies on microbiota-targeted interventions, such as
probiotics, to reduce interpatient variability are required, including
Fig. 13. Scientific projects offered to early stage researchers by the COLOTAN ETN.
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and potential for adverse reactions of these microbiome-based interven-
tions, before they can be validated as effective treatment options.
7. Future outlook
The mission to advance oral absorption research by training a new
generation of scientists will be sustained by the UNGAP network while
exploring several areas of interest in the field: (1) colonic absorption
and drug delivery, (2) GIT physiology and drug delivery in the ageingFig. 14. Scientific projects offered to early
319population and (3) computational and in vitro tools for the eradication
of animal experiments in drug development. Building on the success
of previous public-private research partnership, such as the OrBiTo pro-
ject (funded under the Innovative Medicine Initiative), which was fo-
cused on advanced biopharmaceutics tools and drug developability
classifications, these endeavors are integrated in 3 European training
network (MSCA-ETN) projects that have been approved for funding in
2020 and are presented briefly below.
COLOTAN is a network for “Boosting advanced doctoral training in
innovative colon targeting drugs”. Its overarching goal is to providestage researchers by the AGePOP ETN.
Fig. 15. Scientific projects offered to early stage researchers by the InPharma ETN.
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physiology to improve targeting of drugs to the colon. This program fo-
cuses on innovative technological and scientific developments across a
range of interdisciplinary fields such as (physical, analytical and or-
ganic) chemistry, drug delivery, drug disposition, cell biology, gastroen-
terology, microbiology and modeling and simulation. The scientific
projects offered to early stage researchers (ESRs) are summarized in
Fig. 13. The COLOTAN consortium consists of leading research groups
from universities and from innovative pharmaceutical companies.
AGePOP is a multidisciplinary training and research programme for
elucidating “Drug Absorption in Geriatric Patients and Older People”.
AGePOP will generate information on the actual dosage form intake
conditions for older people and geriatric patients and on physiological
characteristics of their GIT relevant to oral drug absorption. Based on
relevant data, AGePOP will then deliver novel in vitro and in silico
tools for the evaluation of oral drug products for older people and geri-
atric patients. The consortium brings together expertise from academia,
industry and clinics and will train 11 ESRs to become the first highly-
qualified scientists experienced in the development of safe and effective
oral drug products for the advanced age population, see Fig. 14 for the
scientific projects offered.
Another recent example of a pan-European research consortium
that will advance research in biopharmaceutics is the newly announced
InPharma European Industrial Doctorate network (funded under the
H2020-MSCA-ITN-2020), see Fig. 15. Based on the success of the
PEARRL project for streamlining formulation development and regula-
tory tools (funded as an MSCA ITN from 2016 to 2020), the InPharma
consortium is working towards developing a fully integrated, end-to-
end modeling approach to the development of oral drug products. The
research objective is to link data emerging from drug discovery into
computational models that can predict the optimal formulation design
(in Work Package 1), and subsequently integrate biorelevant in vitro
input for formulation prototypes into in silico PBPK models to predict
formulation performance in simulated human clinical trials (Work
Package 2), thus side-stepping the use of animals in oral drug develop-
ment. InPharma will therefore advance the use of computational tools
in drug developability decisions, and at the same time support the320collective societal goal of reducing pre-clinical testing of prototype for-
mulations in animals. The InPharma network, will bring together the
complementary expertise of six multi-national pharmaceutical compa-
nies, five academic research institutions and eight partner organizations
to collaborate on achieving the overall project goals.
8. Concluding remarks
The challenges in oral delivery of medicines, with appropriate con-
sideration of safety, cost and effectiveness, generates opportunities for
enterprise and collaboration. In order to accommodate the need to sig-
nificantly strengthen and advance drug innovation in support of public
health [510,511], adjusted models and the improved organisation of
pharmaceutics research will be needed to generate innovative and ap-
propriate methodology, address niche areas and broadcast knowledge
to the public. The UNGAP programme is an example of a vehicle in
which information relevant to oral drug absorption and nutrition is
freely exchanged, scientists find ways to advance and disseminate
knowledge and training for the next generation and discoveries
are made.
The research efforts within UNGAP build on a multi-disciplinary ap-
proach covering the journey from discovery of a new molecule to the
development of the final drug product, applying a broad framework of
therapy-driven drug delivery scenarios [408].
Focused on the needs of specific age and patient populations by ini-
tiating broad academic/industry collaboration in the development of
relevant in vitro and in silico techniques linked to in vivo ontogeny and
disease states, important steps were taken in a move towards a more
patient-centric drug delivery paradigm. In order to finetune the formu-
lation development approach, the specificities of the different parts in
the GIT have been thoroughly characterized and translated into appro-
priate in vitro and predictive in silico characterization techniques. The
aim was to leverage available and emerging technologies in the under-
standing of the gastrointestinal absorption of a broad spectrum of com-
pounds including small pharmaceutical molecules, nucleic acids and
peptides. The sameprinciples have been applied to study the interaction
between medication and food, which resulted in engagement with
Z. Vinarov, B. Abrahamsson, P. Artursson et al. Advanced Drug Delivery Reviews 171 (2021) 289–331other science networks, leading to active implementation of knowledge
arising from the intestinal microbiome exploration and novel computa-
tional in silico simulations.
In conclusion, this UNGAP position paper used the wide member-
ship across European pharmaceutical scientists, nutritionists, gastroen-
terologists, physical scientists and biochemists to explore five areas,
which require interdisciplinary input. These scope the pharmaceutics-
based medicines research from the dose to the patient at a dinner
table and allow a better understanding of the drug absorption process.
A fundamental problem has been that the gut is a black box, not easily
accessible and the absorption process is a conundrum, with rate-
limiting processes occurring at various dynamic boundaries which
might not be the same in each individual. Once we attempt to increase
patient convenience bymoving to sustained release products or address
the needs of specific patient groups, a new set of problems emerges. Ad-
vanced medicines for specific patient populations, with increased spec-
ificity in terms of regional targetingwith differences observed in the fed
or fasted state and sensible in silico or in vitro tools summarizes in one
sentence the global picture we have tackled. In the future, if the models
of medicine need to change to further advance public health, an inter-
disciplinary effort with similar (or even wider) breadth and scope
would be required.
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